



US 20150005607A1

(19) **United States**

(12) **Patent Application Publication**  
**Cui et al.**

(10) **Pub. No.: US 2015/0005607 A1**

(43) **Pub. Date: Jan. 1, 2015**

(54) **BIOMIMETIC COATING FOR NEURAL IMPLANTS**

**Publication Classification**

(71) Applicants: **Xinyan T. Cui**, Wexford, PA (US); **Carl F. Lagenaur**, Pittsburgh, PA (US); **Erdrin Azemi**, Sunnyvale, CA (US); **Noah R. Snyder**, Glenshaw, PA (US)

(51) **Int. Cl.**  
*A61L 31/10* (2006.01)  
*A61B 5/04* (2006.01)  
*A61N 1/05* (2006.01)  
*A61L 31/16* (2006.01)

(72) Inventors: **Xinyan T. Cui**, Wexford, PA (US); **Carl F. Lagenaur**, Pittsburgh, PA (US); **Erdrin Azemi**, Sunnyvale, CA (US); **Noah R. Snyder**, Glenshaw, PA (US)

(52) **U.S. Cl.**  
CPC ..... *A61L 31/10* (2013.01); *A61L 31/16* (2013.01); *A61B 5/04001* (2013.01); *A61N 1/0551* (2013.01); *A61N 1/0534* (2013.01); *A61L 2300/606* (2013.01)  
USPC ..... **600/372**; 530/391.1; 607/115; 607/62

(73) Assignee: **University of Pittsburgh - Of the Commonwealth System of Higher Education**, Pittsburgh, PA (US)

(57) **ABSTRACT**



(21) Appl. No.: **14/317,271**

(22) Filed: **Jun. 27, 2014**

**Related U.S. Application Data**

(60) Provisional application No. 61/841,223, filed on Jun. 28, 2013.

Disclosed herein are neural probes comprising an L1 polypeptide functional fragment thereof on the exterior surface of the probe, devices including such electrodes, and methods of their use. The disclosed embodiments are useful, for example, for in methods of recording and/or stimulating neural signals in a subject.









FIG. 2A





FIG. 2B












FIG. 3












FIG. 7














FIG. 9












FIG. 13






FIG. 15A

FIG. 15B




FIG. 15C

FIG. 15D




FIG. 15E






FIG. 15F








FIG. 17A

FIG. 17B




FIG. 17C

FIG. 17D




FIG. 18A




FIG. 18B




FIG. 19

FIG. 20B




FIG. 20A

FIG. 20D

FIG. 20C

FIG. 21A




FIG. 21B




FIG. 21C

Surface	O:Cl Ratio	N:Cl Ratio
Oxygen Plasma Treatment	2.04	1.38
EDC/NHS Chemistry	2.34	1.89
Protein Coupling	3.61	2.57




FIG. 22



FIG. 23A





FIG. 23B






FIG. 24




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D

## BIOMIMETIC COATING FOR NEURAL IMPLANTS

### CROSS REFERENCE TO RELATED APPLICATIONS

**[0001]** This application claims priority to U.S. Provisional Application No. 61/841,223, filed Jun. 28, 2013, which is incorporated by reference in its entirety.

### ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

**[0002]** This invention was made with government support under Grant No. NS062019 awarded by the National Institutes of Health and Grant No. N66001-12-C-4027 from the Defense Advances Research Projects Agency. The government has certain rights in the invention.

### FIELD

**[0003]** The present disclosure relates to the field of physiological monitoring and stimulation of neural signals. In some embodiments, a neural probe including a protein coating is provided to increase the quality and quantity of recorded and/or stimulated neural signals.

### BACKGROUND

**[0004]** Chronic neural implants, such as drug delivery devices, diagnostic sensors or neural probes, ideally minimize detrimental tissue responses and impairment of neural function throughout the entire implantation life of the implant. This challenge is particularly critical for neural probes, which are implanted in neural tissue and include electrodes that interface with biological host neurons. The recording and stimulation performance of currently available neural probes and devices including them decreases over time when chronically implanted for long-term clinical applications. Thus, a need exists for improved neural probes and devices incorporating such probes for chronic implantation and long-term clinical application to facilitate recording and stimulation performance that is more reliably maintained for prolonged periods of time.

### SUMMARY

**[0005]** Disclosed herein are neural probes comprising one or more electrodes, an insulating layer, and an effective amount of an L1 polypeptide or functional fragment thereof on an exterior surface of the probe, devices including such probes, and methods of their use. In several embodiments, the insulating layer is a parylene C insulating layer and the L1 polypeptide or functional fragment thereof can be conjugated to the parylene C insulating layer. The probes and devices are unexpectedly useful for neural recording and/or stimulation. Unlike prior electrodes and devices, the disclosed embodiments allow for neural recordings of increased quality and quantity of neural recordings over time, and for a surprisingly long duration for which an implanted device can be used for effective neural recording and stimulation.

**[0006]** In several embodiments, a method of recording and/or stimulating a neural signal in a subject is provided. The method comprises implanting a neural probe for recording and/or stimulating the neural signal into neuronal tissue in the subject. The probe comprises one or more electrodes comprising a surface exposed to the exterior of the probe and

insulated electrical conductors having non-insulated ends, wherein the electrical conductors extend through the probe and one or more of the non-insulated ends contact the electrodes. The probe also comprises a parylene C insulating layer coating a portion of the exterior surface of the probe, except for the surface of the electrodes exposed to the exterior of the probe, and an effective amount of L1 polypeptide or a functional fragment thereof on the exterior surface of the probe. The method further includes connecting the probe to a recording and/or stimulating apparatus via one or more electrical leads; and recording and/or stimulating the neural signal from the neuronal tissue. In additional embodiments, the method comprises recording and/or stimulating the neural signal after the probe has been implanted in the neuronal tissue for at least one year, for example the method can comprise recording at least four sortable neural units from at least one electrode on the probe after the probe has been implanted in the neuronal tissue for at least one year.

**[0007]** In other embodiments, a neural probe for recording and/or stimulating a neural signal in a subject is provided. The neural probe comprises one or more electrodes comprising a surface exposed to the exterior of the probe and insulated electrical conductors having non-insulated ends, wherein the electrical conductors extend through the probe and one or more of the non-insulated ends contact the electrodes. The probe also comprises a parylene C insulating layer coating a portion of the exterior surface of the probe, except for the surface of the electrodes exposed to the exterior of the probe, and an effective amount of L1 polypeptide or a functional fragment thereof on the exterior surface of the probe.

**[0008]** In some embodiments, the effective amount of the L1 polypeptide or functional fragment thereof comprises an amount of the L1 polypeptide or a functional fragment thereof sufficient to allow recording of at least four sortable neural units from at least one electrode after the probe has been implanted for at least six months. In further embodiments, the L1 polypeptide or functional fragment thereof is conjugated to the insulating layer. In more embodiments, the probe comprises from about 0.1 ng/mm<sup>2</sup> to about 2.0 ng/mm<sup>2</sup> L1 polypeptide or functional fragment thereof on the exterior surface. In some embodiments, the L1 polypeptide comprises or consists of the amino acid sequence set forth as SEQ ID NO: 1, or an amino acid sequence at least 90% identical to SEQ ID NO: 1. In additional embodiments, the functional fragment of the L1 polypeptide comprises or consists of the extracellular domain of L1, such as a polypeptide including an amino acid sequence at least 90% identical to amino acids 20-1120 of SEQ ID NO: 1. In some embodiments, the L1 polypeptide is purified from neuronal tissue.

**[0009]** In several embodiments, the neural probe or a plurality thereof is included in a device for recording and/or stimulating a neural signal in a subject. In some embodiments, the device is a microarray for recording and/or stimulating a neural signal, or a deep brain stimulator. Methods of making the disclosed neural probes and devices are also disclosed.

**[0010]** The foregoing and other objects, features, and advantages of the embodiments will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

### BRIEF DESCRIPTION OF THE FIGURES

**[0011]** The patent or application file contains at least one drawing executed in color. Copies of this patent or patent

application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

**[0012]** FIGS. 1A-1D show a graph and a set of images illustrating the quantification of cell adhesion with different probe surface modifications. Parylene-C-treated microwires coated with L1, Plasma, or Laminin were added to primary neuron, microglia or astrocyte cultures and cell-type specific staining was used to identify the cell types attached to each surface. Cell numbers were calculated by dividing the total number of cells by the surface area. Significant increases in neuronal adhesion were observed with L1 and laminin. Error bars represent the mean $\pm$ standard error of the mean (SEM). \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

**[0013]** FIGS. 2A and 2B show a set of immunofluorescence images illustrating neurofilament 200 kD (NF200; red; a neuronal cell marker) and Iba-1 (green; a non-neuronal cell marker) expression in the spinal cord following implant of non-modified (NM) and L1-coated neural probes. NF200 staining was lacking in the area immediately surrounding the implant site and differences were assessed by measuring the size of the area void of this staining. Iba-1-positive cells were localized around the implant site and this immunoreactivity quantified and compared. (A) Representative images at the 1 week (or acute) time point. (B) Representative images at the 4 week (or chronic) time point. Scale bars represent 100  $\mu$ m.

**[0014]** FIG. 3 shows a graph illustrating quantification of the kill zone size in the spinal cord in non-modified and L1 coated neural probes. 4',6-diamidino-2-phenylindole (DAPI)-stained images were used to define the perimeter of each implant and NF200-stained images used to identify the presence of neuronal processes. Kill zone size was computed in 10 degree bins around the 360 degree perimeter of the implant site by calculating the distance between the location of NF200 staining and the location of the implant. These distance measures were used to calculate the mean kill zone size and compared via the rank sum test. Significant decreases in kill zone size were observed with the L1 coating at both 1 week and 4 week time points. \*\*\* $p < 0.001$ .

**[0015]** FIGS. 4A and 4B show a set of graphs illustrating Iba1 staining intensity as a function of distance from the electrode-tissue interface in the spinal cord. MATLAB was used to determine the decline in Iba1 staining intensity at 1 week (A) and 4 week (B) time points. The perimeter of the implant site was defined using the DAPI-stained images. Threshold values based on 95% of the background staining for each section were established, and Iba1 staining above this threshold measured as a function of distance from the implant site. The median intensity values were calculated in 50  $\mu$ m bins and compared via the rank sum test. Significant increases were observed with the L1 coating at the 1 week time point. At 4 weeks, the L1 coating was associated with significant decreases in Iba1 staining. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

**[0016]** FIGS. 5A and 5B show a set of immunofluorescence images illustrating Glial fibrillary acidic protein (GFAP; green; an astrocyte marker) and vimentin (red) expression in spinal cord following implant of NM and L1-coated neural probes. GFAP staining was characterized by the formation of a sheath not located to the area immediately surrounding the implant. Vimentin-positive cells were localized around the implant site with some co-localization with GFAP. (A) Rep-

resentative images at the 1 week (or acute) time point. (B) Representative images at the 4 week (or chronic) time point. Scale bars represent 100  $\mu$ m.

**[0017]** FIGS. 6A and 6B show a set of graphs illustrating GFAP staining intensity as a function of distance from the electrode-tissue interface in the spinal cord. MATLAB was used to determine the decline in GFAP staining intensity at 1 week (A) and 4 week (B) time points. The perimeter of the implant site was defined using the DAPI-stained images. Threshold values based on 95% of the background staining for each section were established and GFAP staining above this threshold measured as a function of distance from the implant site. The median intensity values were calculated in 50  $\mu$ m bins and compared via the rank sum test. Significant increases were observed with the L1 coating at both 1 week and 4 weeks. \* $p < 0.05$ ; \*\* $p < 0.01$ .

**[0018]** FIG. 7 shows a set of immunofluorescence images illustrating the co-localization of neuronal nuclei (NeuN, red) and activated caspase-3 (green) in the spinal cord following implant of NM and L1-coated neural probes. The number of NeuN/caspase-3 positive cells was quantified and reported as a percentage of the total number of NeuN positive cells. Scale bars represent 100  $\mu$ m.

**[0019]** FIGS. 8A and 8B show a set of immunofluorescence images illustrating NF200 (red) and Iba-1 (green) expression in the dorsal root ganglion (DRG) following implant of NM and L1-coated neural probes. NF200 staining was lacking in the area immediately surrounding the implant site and differences assessed by measuring the size of the area void of this staining. Iba1-positive cells were localized around the implant site and this increased immunoreactivity quantified and compared. (A) Representative images at the 1 week (or acute) time point. (B) Representative images at the 4 week (or chronic) time point. Scale bars represent 100  $\mu$ m.

**[0020]** FIG. 9 shows a graph illustrating quantification of the kill zone size in the DRG in non-modified and L1 coated neural probes. DAPI-stained images were used to define the perimeter of each implant and NF200-stained images used to identify the presence of neuronal processes. Kill zone size was computed in 10 degree bins around the 360 degree perimeter of the implant site by calculating the distance between the location of NF200 staining and the location of the implant. These distance measures were used to calculate the mean kill zone size and compared via the rank sum test. Significant decreases in kill zone size were observed with the L1 coating at both 1 week and 4 week time points. \*\*\* $p < 0.001$ .

**[0021]** FIG. 10 shows a set of graphs illustrating Iba1 staining intensity as a function of distance from the electrode-tissue interface in DRG following implant of NM and L1-coated neural probes. MATLAB was used to determine the decline in Iba1 staining intensity at 1 week (A) and 4 week (B) time points. The perimeter of the implant site was defined using the DAPI-stained images. Threshold values based on 95% of the background staining for each section were established, and Iba1 staining above this threshold measured as a function of distance from the implant site. The median intensity values were calculated in 50  $\mu$ m bins and compared via the rank sum test. Significant decreases were observed with the L1 coating at the 1 week time point. At 4 weeks, the L1 coating was associated with significant increases in Iba1 staining. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

**[0022]** FIGS. 11A and 11B show a set of immunofluorescence images illustrating GFAP (green) and vimentin (red) expression in the DRG following implant of NM and

L1-coated neural probes. GFAP staining was characterized by the formation of a sheath not located to the area immediately surrounding the implant. Vimentin-positive cells were localized around the implant site with some co-localization with GFAP. (A) Representative images at the 1 week (or acute) time point. (B) Representative images at the 4 week (or chronic) time point. Scale bars represent 100  $\mu\text{m}$ . FIGS. 12A and 12B show a set of graphs illustrating GFAP staining intensity as a function of distance from the electrode-tissue interface in the dorsal root ganglion. MATLAB was used to determine the decline in GFAP staining intensity at 1 week (A) and 4 week (B) time points. The perimeter of the implant site was defined using the DAPI-stained images. Threshold values based on 95% of the background staining for each section were established and GFAP staining above this threshold measured as a function of distance from the implant site. The median intensity values were calculated in 50  $\mu\text{m}$  bins and compared via the rank sum test. With L1, significant decreases were observed with the L1 coating at 1 week while significant increases were observed at 4 weeks. \* $p < 0.05$ ; \*\* $p < 0.01$ .

[0023] FIG. 13 shows a set of immunofluorescence images illustrating co-localization of NeuN and activated caspase-3 in the DRG. Immunofluorescence images were used to determine the degree of co-localization between NeuN (red) and cleaved caspase-3 (green); representative images are provided. The number of NeuN/caspase-3 positive cells was quantified and reported as a percentage of the total number of NeuN positive cells. Scale bars represent 100  $\mu\text{m}$ .

[0024] FIGS. 14A-14I shows a series of immunofluorescence images and graphs illustrating brain tissue response to non-modified and L1 coated NeuroNexus probes (from the NeuroNexus training kit, with linear silicon shank) in comparison to uncoated controls. Neuronal density is maintained at the vicinity of the probe track (A) while a kill zone is found around the control (B), as illustrated by NeuN staining. Axonal growth is enhanced around the L1 probe (C) while control probes had a lower neurofilament staining (D), as illustrated by NF200 staining. Explanted L1 probes show direct neuron attachment as indicated by  $\beta$ -III-tubulin staining (E) while the control probes were covered with cells that are not neuronal (F), as illustrated by  $\beta$ -tubulin (green) and DAPI (blue) staining. Quantitative image analysis showed different markers of reactive tissue responses. The intensities of the staining were averaged across sections and animals, normalized to control tissue and plotted against distance to the probe-tissue interface for GFAP (G), vimentin (H) and ED-1 (I).

[0025] FIGS. 15A-15F show a series of immunofluorescence images, schematic diagrams and a graph illustrating L1 coating on parylene C coated neural probes. (A) Green fluorescent antibody staining verifying the protein presence on the microwire probe. (B) Neurons growing on L1 coated microwire shown by staining of  $\beta$ -tubulin (green) and nuclei (DAPI, blue). (C) Quantification of different cell attachment and (D) neurons growing on L1 coated parylene C surfaces that were pre-soaked in media at physiological condition for 5 days, the L1's biological effect is reserved. (E) Illustration of a first approach for covalently attaching L1 to the neural probe where carboxylic acid groups are created followed by protein/peptide binding. (F) Illustration of an additional approach for covalently attaching L1 to neural probes where reactive parylene is created with amine groups for protein binding.

[0026] FIGS. 16A-16D illustrate the coating of an electrode site with conductive polymer functionalized with biomolecules for attracting neuronal growth to the neural electrodes. (A) Polyethylenedioxythiophene (PEDOT) coating doped with L1 on the bottom electrode, anti-L1 staining (red) showed that presence of L1 on the PEDOT coating by the red fluorescence. (B) Scanning Electron Microscopy (SEM) of PEDOT/L1, (C) scheme of PEDOT/GO functionalization and (D) PEDOT/GO functionalized with neuroadhesive peptide promoted neuron attachment ( $\beta$ -tubulin III, green and nuclei (DAPI), blue staining is shown).

[0027] FIGS. 17A-17D show results from chronic recording from L1 coated and non-coated  $10 \times 10$  Utah arrays (UEA) implanted into the motor cortex of a single monkey. (A) L1 coated array (left) detected significantly greater number of single units compared to non-coated array (right) over time. At 75 days, L1 coated array records over an order of magnitude greater number of sorted units. (B) seven distinguishable single units detected from a single channel of the L1 coated array. (C) representative channel shows stable single-unit (tuning and waveform shape) over days. (D) Histogram of the largest single-unit signal amplitude per channel in the L1-coated UEA 2.5 months after implantation. Two channels have amplitude  $> 1$  mV and only 3 channels have amplitude  $< 200$   $\mu\text{V}$ .

[0028] FIGS. 18A and 18B are graphs showing continued results from chronic recording from the L1 coated and non-coated  $10 \times 10$  Utah arrays (UEA) implanted into the motor cortex of the monkey as shown in FIG. 17. (A) L1 coated array detected single units over 18 months of ongoing chronic recording. (B) On some channels, unit waveforms are very stable and signal amplitudes are extraordinarily large even at day 447.

[0029] FIG. 19 shows a schematic diagram depicting the domains of L1.

[0030] FIGS. 20A-20D show light microscopy images illustrating the L1 coating stability under varying conditions. (A) L1 coated parylene C, (B) L1 coating exposed to overnight ethylene oxide sterilization, (C) L1 coating dried at room temperature, and (D) L1 'lightly' crosslinked with enzymatic production of superoxide.

[0031] FIGS. 21A-21C show a schematic diagram, graph and table illustrating attachment of L1 to parylene C coated substrates using ethyl(dimethylaminopropyl) carbodiimide (EDC)/N-Hydroxysuccinimide (NHS) crosslinking following oxygen plasma treatment.

[0032] FIG. 22 shows an immunofluorescence image illustrating neuron growth on parylene-C and L1 coated coverslips that were produced by treatment of parylene-C coated coverslips with oxygen plasma, followed by covalent attachment of L1 to the activated parylene C by ethyl(dimethylaminopropyl) carbodiimide (EDC)/N-Hydroxysuccinimide (NHS) crosslinking.

[0033] FIGS. 23A and 23B show immunofluorescence images illustrating that L1 purified from rat brain (FIG. 23A) and human L1 produced recombinantly by expression in HEK293 cells (FIG. 23B) can support neuron growth. The L1 preparations were conjugated to parylene-C coated coverslips using the oxygen plasma initiated EDC/NHS coupling method described herein.

[0034] FIG. 24 shows a light microscopy image illustrating growth of neurons on a coverslip coated with parylene C and recombinant human L1 produced in HEK293 cells.

**[0035]** FIGS. 25A-25D illustrate an exemplary method of making a neural probe as provided herein.

#### SEQUENCE LISTING

**[0036]** The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. The Sequence Listing is submitted as an ASCII text file in the form of the file named "Sequence.txt" (~40 kb), which was created on Jun. 27, 2014, which is incorporated by reference herein. In the accompanying sequence listing:

#### DETAILED DESCRIPTION

##### I. Introduction

**[0037]** The recording and stimulation performance of currently available neural recording and stimulation devices decreases over time. For example, clinical grade Blackrock arrays in monkey motor cortex were found to have a 2.4% drop per month in signal amplitude (see, e.g., Chestek et al., "Long-term stability of neural prosthetic control signals from silicon cortical arrays in rhesus macaque motor cortex," *J Neural Eng.*, 8(4): p. 045005, 2011, incorporated by reference herein in its entirety). Many factors contribute to failure in chronic implants, including implantation procedure, implant size and geometry, mechanical mismatch, connector or packaging failure, and material degradation. While most of these factors have been improved over the years of accumulated experience and continue to show promising improvements, the most significant challenge is the issue of biocompatibility. In repeated studies by multiple groups, brain tissue response, particularly neuronal loss and chronic inflammation around the implant have been observed in the vicinity of implanted electrodes, which are believed to contribute to chronic recording failure.

**[0038]** Implanted neural probes include electrodes that detect neuronal action potentials by detecting extracellular electrical potential changes (10's to 100's of microvolt) in reference to a ground. The closer the electrode is to a neuron, the better signal strength and quality of neural signals that can be recorded from the electrode. It is reported that 50-100  $\mu\text{m}$  is the maximum distance that a microelectrode can obtain measurable signals from a neuron. For high quality long-term stable recording, the proximity of electrodes to neurons needs to be maintained over time. However, repeated immunohistology studies by multiple groups have shown "kill zones" around neural implants, where neural densities have significantly lowered around the implant (see, e.g. Edell et al., *IEEE Trans. Biomed. Eng.*, 1992. 39: p. 635-643; and Szarowski et al., *Brain Research*, 2003. 983(1-2): p. 23-35; Turner et al., *Experimental neurology*, 1999. 156: p. 33-49, each of which is incorporated by reference herein). The electrode then has to detect neural signal from further away (beyond the kill zone) leading to lower yield of single-unit and recorded amplitude of neural signals.

**[0039]** Many different biomaterial strategies have been developed to improve the tissue response to neural probe implantation but the success in improved recording has been limited (see, e.g., Kim et al., *Acta Biomater.* 6(1): p. 57-62;

Ludwig et al., *J Neural Eng.* 2006. 3(1): p. 59-70; Seymour and Kipke, *Conf Proc IEEE Eng Med Biol Soc.* 2006. 1: p. 4606-9; Purcell et al., *J Neural Eng.* 2009. 6(2): p. 026005; Purcell et al., *J Neurosci Methods*, 2009. 183(2): p. 149-57; Kozai et al., *Nat Mater*, 2012. 11(12): p. 1065-73; and Renaker et al., *J Neural Eng.* 2007. 4(2): p. L1-5, each of which is incorporated herein).

**[0040]** It is generally believed that many factors contribute to the low yield and poor longevity of current neural implants, including, but not limited to, insertion trauma, surface chemistry, mechanical mismatch, persistent blood-brain leakage associated with the implants, and material failure. It is expected that it would take a combinatorial approach that addresses more than one of the above problems to achieve a substantial improvement in recording performance (see, e.g., Polikov, Tresco, and Reichert, *J Neurosci Methods*, 2005. 148(1): p. 1-18.). Surprisingly, the disclosed strategies to improve the recording and stimulation performance of neural probes utilizing a simple improvement—including L1 polypeptide, a brain-derived neuronal adhesion molecule, or a functional fragment thereof, on the exterior surface of the neural probe. In several embodiments, the probe includes a parylene C insulating layer, and the L1 polypeptide or functional fragment thereof is conjugated to the exterior surface of the parylene C layer. The disclosed improvements in neural probe technology unexpectedly provide for increased quality and quantity of neural recordings over time, and for a surprisingly long duration for which an implanted probe can be used for effective neural recording and stimulation.

##### II. Summary of Terms

**[0041]** Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, *Genes X*, published by Jones & Bartlett Publishers, 2009; and Meyers et al. (eds.), *The Encyclopedia of Cell Biology and Molecular Medicine*, published by Wiley-VCH in 16 volumes, 2008; and other similar references. As used herein, the term "comprises" means "includes." It is further to be understood that any and all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for descriptive purposes, unless otherwise indicated. Although many methods and materials similar or equivalent to those described herein can be used, particular suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. The scope of the claims should not be limited to those features exemplified. To facilitate review of the various embodiments, the following explanations of terms are provided:

**[0042]** Coat: A layer of material that partially or fully covers a surface. For example, an insulating layer can fully coat the exterior surface of an electrical conductor with a non-conductive material to facilitate conduction of neural signals along the conductor.

**[0043]** In several embodiments, the neural probes disclosed herein include an external surface with a coat of L1-polypeptide or functional fragment thereof on an external surface. An "L1-coated probe" includes an effective amount of L1 polypeptide or a functional fragment on its exterior surface. The probe does not need to be completely coated with L1 (an in many cases is partially coated); the amount of L1 polypeptide or functional fragment thereof included in an "L1-coat"

on the external surface of a probe can vary according to the application parameters, e.g., time of use, exposure, level of signals, levels of noise, desired protein density, etc. Coating material can be applied to an underlying surface in various ways known in the art and describe herein. Non-limiting examples of methods that can be used to apply the L1 polypeptide or functional fragment thereof to the external surface of the probe include coating methods such as dipping, spraying, painting, vacuum deposition, conjugation to the external surface of the probe (e.g., by conjugation to the insulating layer, discussed in more detail below), or by any other method known to those of ordinary skill in the art.

**[0044]** Conservative variants: “Conservative” amino acid substitutions are those substitutions that do not substantially alter the biological function of a protein, such as substitutions that do not substantially decrease the bioactivity of a L1 polypeptide. For example, a human L1 polypeptide can include at most about 1, at most about 2, at most about 5, at most about 10, at most about 15, at most about 20, at most about 30, at most about 40, or at most about 50 conservative substitutions and still retain bioactivity needed to improve recording and/or stimulation of neural signals as disclosed herein. The term conservative variation also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid.

**[0045]** Conservative amino acid substitution tables providing functionally similar amino acids are well known to one of ordinary skill in the art. The following six groups are examples of amino acids that are considered to be conservative substitutions for one another:

**[0046]** 1) Alanine (A), Serine (S), Threonine (T);

**[0047]** 2) Aspartic acid (D), Glutamic acid (E);

**[0048]** 3) Asparagine (N), Glutamine (Q);

**[0049]** 4) Arginine (R), Lysine (K);

**[0050]** 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

**[0051]** 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

**[0052]** Effective amount: The amount of an agent (such as a L1 polypeptide or functional fragment thereof) that alone, or together with one or more additional agents, induces the desired response, such as, for example, increased recording and/or stimulation of neural signals as disclosed herein.

**[0053]** Electrode: An electric conductor through which an electric current can pass. An electrode can also be a collector and/or emitter of an electric current. In some embodiments, an electrode is a solid and comprises a conducting metal as the conductive layer. Non-limiting examples of conducting metals include noble metals and alloys, such as stainless steel and tungsten. An “array of electrodes” refers to a device with at least two electrodes formed in any pattern. The electrodes can be either interconnected or independently wired.

**[0054]** Implanting: Completely or partially placing a neural probe or device including a neural probe within a subject, for example, using surgical techniques. A device or probe is partially implanted when some of the device or probe reaches, or extends to the outside of, a subject.

**[0055]** Implantable probes and devices may be implanted into neural tissue, such as the central nervous system, more particularly the brain, for treatment of different medical conditions and for various time periods. A neural probe or device can be implanted for varying durations, such as for a short term duration (e.g., one or two days or less) or for long-term or chronic duration (e.g., one month or more).

**[0056]** Isolated: A biological component (such as a nucleic acid, peptide, protein or protein complex, for example an antibody) that has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs, that is, other chromosomal and extra-chromosomal DNA and RNA, and proteins. Thus, isolated nucleic acids, peptides and proteins include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell, as well as, chemically synthesized nucleic acids. A isolated nucleic acid, peptide or protein, for example an antibody, can be at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% pure.

**[0057]** L1: A type-1 transmembrane protein also known as L1CAM that is a member of the immunoglobulin superfamily. L1 is known to be involved in axon outgrowth and fasciculation, neuronal migration and survival, synaptic plasticity and regeneration after trauma, and can interact with itself (homophilic) but also with a variety of heterophilic ligands such as integrins, CD24, neurocan, neuropilin-1 and other members of the neural cell adhesion family. (For review, see Schmid and Maness, *Curr Opin. Neurobiol.*, 18, 245-250, 2008; Maness et al., *Nat Neurosci*, 10:19-26, 2007, and Figge et al., *Mol Cell Neurosci*, 2011).

**[0058]** The L1 family of cell adhesion molecules includes at least four different L1-like proteins, including L1, CHL1 (close homologue of L1), Neurofascin, and NrCAM (Ng-CAM related cell adhesion molecule). The amino acid sequence of these proteins are known, and are publically available as GenBank Accession Nos. NP\_000416.1 (L1), BC047244.1 (NCAM1), AAI43497 (CHL1), 094856 (Neurofascin), each of which is incorporated by reference herein in its entirety. Several embodiments include a functional fragment of L1. As used herein, a “functional fragment of L1” is a polypeptide including less than the full amino acid sequence of mature L1, and which can be conjugated to a parylene C insulated electrode to generate a L1-coated electrode that provides a similar effect on neural signal recording as that of a control electrode including a parylene C insulating layer conjugated to L1 purified from neural tissue (as described in Example 1, below).

**[0059]** Standard methods in the art can be used to produce an L1 polypeptide or functional fragment thereof, including expression of recombinant L1 or a functional fragment thereof using molecular biology techniques, or purification of L1 from neural tissue (e.g., as described in Lagenaur and Lemmon, V, *An L1-like molecule, the 8D9 antigen is a potent substrate for neurite extension*. *Proc. Natl. Acad. Sci. USA*, 84:7753-7757, 1987).

**[0060]** Neural probe: A device or component of a device including one or more electrodes that can be placed in contact with neuronal tissue in an animal host and can record and/or stimulate neural signals from or to the neuronal tissue. Neural probes typically include conductive and non-conductive surfaces designed for contact with neuronal tissue when implanted in a subject, and can include one or more electrodes that can be independently monitored from other conductive surfaces on or off the probe) for recording and/or stimulating neural signals. In several embodiments, the disclosed probes are included in a device (such as an array or a deep brain stimulator) for recording and/or stimulating a neural signal in a subject.



**[0061]** Neural signal: An electrical signal originating in the nervous system of a subject. "Recording a neural signal" refers to recording an electrical signal that independently exists outside of the membrane or wall of a cell. "Stimulating a neural signal" refers to application of an electrical current to the neural tissue of a subject in such a way as to cause neurons in the subject to produce an electrical signal (e.g., an action potential). An extracellular electrical signal can, however, originate in a cell, such as one or more neural cells. An extracellular electrical signal is contrasted with an intracellular electrical signal, which originates, and remains, in a cell. An extracellular electrical signal can comprise a collection of extracellular electrical signals generated by one or more cells. The person of ordinary skill in the art is familiar with methods for recording electrical signals using a device including an implanted electrode.

**[0062]** Nucleic acid: A polymer composed of nucleotide units (ribonucleotides, deoxyribonucleotides, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof) linked via phosphodiester bonds, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof. Thus, the term includes nucleotide polymers in which the nucleotides and the linkages between them include non-naturally occurring synthetic analogs, such as, for example and without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), and the like. Such polynucleotides can be synthesized, for example, using an automated DNA synthesizer and/or constructed using standard molecular biology techniques. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which "U" replaces "T."

**[0063]** Conventional notation is used herein to describe nucleotide sequences: the left-hand end of a single-stranded nucleotide sequence is the 5'-end; the left-hand direction of a double-stranded nucleotide sequence is referred to as the 5'-direction. The direction of 5' to 3' addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction. The DNA strand having the same sequence as an mRNA is referred to as the "coding strand;" sequences on the DNA strand having the same sequence as an mRNA transcribed from that DNA and which are located 5' to the 5'-end of the RNA transcript are referred to as "upstream sequences;" sequences on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the coding RNA transcript are referred to as "downstream sequences."

**[0064]** "cDNA" refers to a DNA that is complementary or identical to an mRNA, in either single stranded or double stranded form.

**[0065]** "Encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and non-coding

strand, used as the template for transcription, of a gene or cDNA can be referred to as encoding the protein or other product of that gene or cDNA. Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.

**[0066]** A polynucleotide or nucleic acid sequence refers to a polymeric form of nucleotide at least 10 bases in length. A recombinant polynucleotide includes a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA) independent of other sequences. The nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single- and double-stranded forms of DNA.

**[0067]** Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter, such as the CMV promoter, is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.

**[0068]** Polypeptide: Any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). In one embodiment, the polypeptide is a L1 polypeptide or a functional fragment thereof. A "residue" refers to an amino acid or amino acid mimetic incorporated in a polypeptide by an amide bond or amide bond mimetic. A polypeptide has an amino terminal (N-terminal) end and a carboxy terminal (C-terminal) end.

**[0069]** Polypeptide modifications: polypeptides can be modified by a variety of chemical techniques to produce derivatives having essentially the same activity and conformation as the unmodified peptides, and optionally having other desirable properties. For example, carboxylic acid groups of the protein, whether carboxyl-terminal or side chain, may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form a C<sub>1</sub>-C<sub>16</sub> ester, or converted to an amide of formula NR<sub>1</sub>R<sub>2</sub> wherein R<sub>1</sub> and R<sub>2</sub> are each independently H or C<sub>1</sub>-C<sub>16</sub> alkyl, or combined to form a heterocyclic ring, such as a 5- or 6-membered ring. Amino groups of the peptide, whether amino-terminal or side chain, may be in the form of a pharmaceutically-acceptable acid addition salt, such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts, or may be modified to C<sub>1</sub>-C<sub>16</sub> alkyl or dialkyl amino or further converted to an amide.

**[0070]** Hydroxyl groups of the peptide side chains can be converted to C<sub>1</sub>-C<sub>16</sub> alkoxy or to a C<sub>1</sub>-C<sub>16</sub> ester using well-recognized techniques. Phenyl and phenolic rings of the peptide side chains can be substituted with one or more halogen atoms, such as F, Cl, Br or I, or with C<sub>1</sub>-C<sub>16</sub> alkyl, C<sub>1</sub>-C<sub>16</sub> alkoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids. Methylene groups of the peptide side chains

can be extended to homologous C<sub>2</sub>-C<sub>4</sub> alkylenes. Thiols can be protected with any one of a number of well-recognized protecting groups, such as acetamide groups.

**[0071]** Purified: The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide preparation is one in which the peptide or protein (such as L1 protein) is more enriched than the peptide or protein is in its natural environment within a cell or tissue. In one embodiment, a preparation is purified such that the protein or peptide represents at least 50% of the total peptide or protein content of the preparation, such as at least 80%, at least 90%, at least 95% or greater of the total peptide or protein content.

**[0072]** Recombinant: A recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques. A recombinant protein is a protein encoded by a heterologous (for example, recombinant) nucleic acid that has been introduced into a host cell, such as a bacterial or eukaryotic cell. The nucleic acid can be introduced, for example, on an expression vector having signals capable of expressing the protein encoded by the introduced nucleic acid or the nucleic acid can be integrated into the host cell chromosome.

**[0073]** Sequence identity: The similarity between amino acid sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or variants of a polypeptide will possess a relatively high degree of sequence identity when aligned using standard methods.

**[0074]** Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman and Wunsch, *J. Mol. Biol.* 48:443, 1970; Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85:2444, 1988; Higgins and Sharp, *Gene* 73:237, 1988; Higgins and Sharp, *CABIOS* 5:151, 1989; Corpet et al., *Nucleic Acids Research* 16:10881, 1988; and Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85:2444, 1988. Altschul et al., *Nature Genet.* 6:119, 1994, presents a detailed consideration of sequence alignment methods and homology calculations.

**[0075]** The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., *J. Mol. Biol.* 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.

**[0076]** Terms used to describe sequence relationships between two or more nucleotide sequences or amino acid sequences include "reference sequence," "selected from," "comparison window," "identical," "percentage of sequence identity," "substantially identical," "complementary," and "substantially complementary."

**[0077]** An example of algorithms that are suitable for determining percent sequence identity and sequence similarity are

the BLAST and the BLAST 2.0 algorithm, which are described in Altschul et al., *J. Mol. Biol.* 215:403-410, 1990 and Altschul et al., *Nucleic Acids Res.* 25:3389-3402, 1977. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov). The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLASTP program (for amino acid sequences) uses as defaults a word length (W) of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915, 1989). An oligonucleotide is a linear polynucleotide sequence of up to about 100 nucleotide bases in length.

**[0078]** Subject: Living multi-cellular vertebrate organisms, a category that includes human and non-human mammals, including non-human primates, rats, mice, guinea pigs, cats, dogs, cows, horses, and the like. Thus, the term "subject" includes both human and veterinary subjects.

### III. L1 Coated Probes and Methods of Making and Using Same

**[0079]** A. Probes and Devices for Recording and/or Stimulating Neural Signals

**[0080]** Several embodiments include a neural probe including one or more electrodes for recording and/or stimulating neural signals in a subject. FIGS. 25A-25D illustrate an exemplary probe 2 for use in the disclosed embodiments. As shown in FIG. 25A, the probe 2 can include a distal end 4, a proximal portion 6, and an exterior surface 8. The probe also includes one or more electrodes 10, each electrode having a surface 12 exposed to the exterior of the probe. The one or more electrodes 10 are each connected to an insulated electrical conductor 14 (shown in FIG. 25B) that extends through the probe and has first and second non-insulated ends. The first non-insulated end can be in electrical contact with an electrode 10, and the second non-insulated end can be in electrical contact with a connection portion of the probe (not shown) located at the proximal end of the probe. The connection portion of the probe can be connected to one or more leads for communication of electrical signals from the surface 12 of each electrode via the one or more insulated electrical conductors 14 and the lead to a recording or stimulating apparatus. Alternatively, the connection portion of the probe can be directly connected to the recording and/or stimulation apparatus. The probe includes an insulating layer 16 on its external surface that covers the external portion of the probe except for the surface 12 of the one or more electrodes. The insulating layer can cover the one or more insulated electrical conductors 14. FIG. 25A shows the probe with the insulating layer, and FIG. 25B shows the probe without the insulating layer for illustration purposes.

**[0081]** In the disclosed embodiments, the probe includes an effective amount of L1 polypeptide or a functional fragment thereof on its external surface. The L1 polypeptide or functional fragment thereof can be included in or on the external surface of the probe in any configuration that exposes the L1 polypeptide or functional fragment in a way that allows tissue surrounding an implanted probe to contact the L1 polypeptide or functional fragment thereof. Non-limiting examples of methods that can be used to apply the L1 polypeptide or functional fragment thereof to the external surface of the probe include coating methods such as dipping, spraying, painting, vacuum deposition, conjugation to the external sur-

face of the probe (e.g., by conjugation to the insulating layer, discussed in more detail below), or by any other method known to those of ordinary skill in the art. In another embodiment, the L1 polypeptide or functional fragment thereof can be included in a composition used to make the insulating layer of the probe, and the composition can be applied thereon (e.g., using coating methods) to form the insulating layer of the probe. FIG. 25C illustrates an embodiment of the probe including an effective amount of L1 or a functional fragment thereof (shown with shading 18) in or on the external surface of the probe, wherein the L1 or functional fragment thereof does not cover the surface 12 of the electrode 10 exposed to the exterior of the probe; however, the L1 polypeptide or functional fragment can also be located on the surface 12 of the electrode (shown as shading 20 in FIG. 25D).

**[0082]** In several embodiments, the probe includes an insulating layer on its exterior surface. An “insulating layer” is a layer of non-conductive material deposited onto the exterior surface of the probe. The person of ordinary skill in the art will appreciate that, when the probe is used for recording and/or stimulation of neural signals, the non-conductive insulating layer does not coat the entire surface of the probe, the one or more electrodes included on the probe are exposed to the exterior surface of the probe to record and/or stimulate neural signals in surrounding neural tissue.

**[0083]** Non-limiting examples of materials for non-conductive insulating layers include parylene, silicon oxide, silicon nitride, polyimide, alumina, Teflon (PTFE), fluoropolymer, silicone, fluoro-silicone, or a combination of two or more thereof. In some embodiments, the insulation layer comprises or consists of parylene. In some embodiments, the parylene is parylene C, parylene A, parylene D, parylene N, parylene AF-4, or a combination of two or more thereof. In some embodiments, the insulating layer comprises or consists of parylene C. Methods of making electrodes for recording and/or stimulating a neural signal that are coated (fully or partially) with an insulating layer (including a parylene C insulating layer) are known in the art; see, e.g., U.S. Pat. No. 8,355,802 and WO 2005/114720, which are incorporated by reference herein in their entirety.

**[0084]** The probe includes an effective amount of L1 polypeptide or functional fragment thereof on its exterior surface. In some embodiments, the L1 polypeptide or functional fragment thereof can be conjugated to the exterior surface of the probe (e.g., by conjugation to the insulating layer of the probe). The effective amount of L1 or functional fragment can vary depending on the particular application. In some embodiments, an effective amount of L1 polypeptide or functional fragment is an amount of the L1 polypeptide or functional fragment (e.g., a surface density of L1 polypeptide) sufficient to reduce the deleterious effects on neural recording quality over time (for example over a year), observed with a corresponding electrode that is not conjugated to an effective amount of L1 polypeptide. In additional embodiments, an effective amount of L1 polypeptide or functional fragment thereof includes an amount of L1 polypeptide or a functional fragment thereof on the exterior surface of the probe sufficient to allow recording of at least four sortable neural units from at least one electrode after the probe has been implanted for at least six months.

**[0085]** In some embodiments, the effective amount of L1 or functional fragment includes from about 0.1 ng/mm<sup>2</sup> to about 10.0 ng/mm<sup>2</sup> (such as about 0.1 ng/mm<sup>2</sup> to about 0.5 ng/mm<sup>2</sup>, about 0.5 ng/mm<sup>2</sup> to about 1.0 ng/mm<sup>2</sup>, about 1.0 ng/mm<sup>2</sup> to

about 1.5 ng/mm<sup>2</sup>, about 0.5 ng/mm<sup>2</sup> to about 2.0 ng/mm<sup>2</sup>, about 1.0 ng/mm<sup>2</sup> to about 2.0 ng/mm<sup>2</sup>, about 1.0 ng/mm<sup>2</sup> to about 5.0 ng/mm<sup>2</sup>, about 1.5 ng/mm<sup>2</sup> to about 2.0 ng/mm<sup>2</sup>, about 3.0 ng/mm<sup>2</sup> to about 5.0 ng/mm<sup>2</sup>, about 5.0 ng/mm<sup>2</sup> to about 7.0 ng/mm<sup>2</sup>, about 5.0 ng/mm<sup>2</sup> to about 10.0 ng/mm<sup>2</sup>, about 7.0 ng/mm<sup>2</sup> to about 10.0 ng/mm<sup>2</sup>, or about 1.0 ng/mm<sup>2</sup> to about 3.0 ng/mm<sup>2</sup>) L1 polypeptide or functional fragment thereof on the exterior surface of the probe. In some embodiments, the effective amount of L1 or functional fragment includes from about 0.5 to about 1.0 ng/mm<sup>2</sup> L1 or functional fragment on the exterior surface of the probe. In some embodiments, the effective amount of L1 includes at least 0.2 ng/mm<sup>2</sup> L1 or functional fragment on the exterior surface of the probe (such as at least 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0 ng/mm<sup>2</sup> L1 or functional fragment, or more, on the exterior surface of the probe). Methods of determining the amount of L1 polypeptide on the exterior surface of the probe are known in the art. For example, a density of protein functionalization of ~0.66 ng/mm<sup>2</sup> has been observed for the protein functionalization of silica-based surfaces (Bhatia et al., *Analytical Biochemistry* 178 408-413, 1989, incorporated by reference herein). In some embodiments, dual polarization interferometry can be used to determine the surface bound L1 mass (see, e.g., Azemi et al., *Surface immobilization of neural adhesion molecule L1 for improving the biocompatibility of chronic neural probes: In vitro characterization. Acta Biomaterialia*, 2008, 4(5): p. 1208-1217, which is incorporated by reference herein in its entirety). Additional methods are also available, including, but not limited to, immunostaining of functionalized surfaces, attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), X-ray photoelectron spectroscopy (XPS).

**[0086]** The disclosed probes can be included on a device designed for recording and/or stimulating a neural signal in a subject with neuronal tissue, such as any mammal, including humans, non-human primates, pigs, sheep, cows, rodents and the like.

**[0087]** Numerous types and styles of probes including one or more electrodes for recording and/or stimulating a neural signal are available, and known to the person of ordinary skill in the art. Any probe (or device containing the probe) for recording and/or stimulating neural signals in a subject may be used with the disclosed embodiments. In several embodiments, the probe includes more than one electrode, such as an array of electrodes. In additional embodiments, a device is provided that can include one or more probes, each of which can include one or more electrodes. Non-limiting examples include deep brain stimulators, EcoG grids, electrode arrays, microarrays (e.g., Utah and Michigan microarrays), and microwire electrodes and arrays. Probes (and devices including them) can be inserted into the body, for example transcutaneously, intervertebrally, or transcranially, to a target site in the body (for example, in the brain) where neural signals are to be recorded or stimulated.

**[0088]** Commercial sources of probes and devices for recording and/or stimulating neural signals in a subject, including probes coated with an insulating layer (such as Parylene C), are known. For example, such electrodes and devices are available commercially from Blackrock Microsystems (Salt Lake City, Utah) and NeuroNexus (Ann Arbor, Mich.).

B. L1 Polypeptides and Fragments Thereof

**[0089]** The disclosed probes include an L1 polypeptide or a functional fragment thereof on an exterior surface. In some embodiments the probe is coated with an insulating layer (such as a Parylene C insulating layer), wherein an exterior surface on the insulating layer is conjugated to the L1 polypeptide or a functional fragment thereof.

**[0090]** L1 (also known as L1CAM) is a 200-220 kD glycoprotein and is a member of the immunoglobulin superfamily. This type-1 transmembrane protein includes at least four immunoglobulin like (“Ig-like”) domains at the amino terminal end of the polypeptide followed by five fibronectin type III homologous repeats, a single transmembrane region and a short intracellular domain (see FIG. 19). The Ig domains are known to be involved with L1-L1 homodimerization (Haspel et al., *J Neurosci Res.*, 66:347-355, 2001, incorporated by reference herein in its entirety). At least two splicing variants are known encoding for 1257 and 1253 amino acids proteins. L1 is involved in axon outgrowth and fasciculation, neuronal migration and survival, synaptic plasticity and regeneration after trauma. L1 can interact with itself (homophilic) but also with a variety of heterophilic ligands such as integrins, CD24, neurocan, neuropilin-1 and other members of the neural cell adhesion family. (For review, see Schmid and Maness, L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth,” *Curr Opin. Neurobiol.*, 18, 245-250, 2008; Maness “Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration,” *Nat Neurosci*, 10:19-26, 2007; Figge et al., “Neurite outgrowth triggered by the cell adhesion molecule L1 requires activation and inactivation of the cytoskeletal protein cofilin,” *Mol Cell Neurosci*, 2011; each of which is incorporated by reference herein in its entirety).

**[0091]** Without being bound by theory, in the disclosed embodiments, the L1 polypeptide or functional fragment thereof on the exterior surface of the probe can interact with L1 polypeptide on the surface of cells in the neural tissue of a subject in which the probe is implanted. It is believed that the Ig-like domains 1-4 are involved in the L1-L1 binding. Each is maintained by a disulfide bond (shown in FIG. 19 as s-s). The more cell-membrane proximal fibronectin type domains may contribute to signaling to the cell bearing the L1 but might not be expected to contribute to L1-L1 interaction.

**[0092]** The L1 family of cell adhesion molecules includes at least four different L1-like proteins, which are members of the immunoglobulin superfamily (IgSF CAMs). The members of the L1-family in humans include L1, CHL1 (close homologue of L1), Neurofascin and NrCAM (NgCAM related cell adhesion molecule). Any of the L1 family members (or a functional fragment of such family members) can also be used in the disclosed embodiments in place of L1 (or functional fragment thereof).

**[0093]** In some embodiments the L1 polypeptide or functional fragment thereof includes or consists of one or more of the Ig-like domain of L1, such as 1, 2, 3, or all 4 of the Ig1, Ig2, Ig3, and Ig4 Ig-like domains of L1. In some embodiments, the L1 polypeptide or functional fragment thereof includes or consists of the Ig1, Ig2, Ig3, and Ig4 Ig-like domains of L1. The person of skill in the art can readily determine the amino acid sequence of the Ig-like domains of L1 (for example, this information is available in the GenBank Accession entry for No. NP\_000416.1). In some embodiments, that L1 polypeptide or functional fragment thereof includes or consists of the

L1 extracellular domain. Exemplary regions of the L1 polypeptide as set forth in SEQ ID NO: 1 (which corresponds to the L1 sequence shown in GenBank Accession No. NP\_000416.1) are shown in Table 1, below.

TABLE 1

Regions of L1	
Region	SEQ ID NO: 1 amino acids
Signal peptide	1-19
Ig1	53-130
Ig2	134-228
Ig3	260-330
Ig4	347-422
Extracellular region	20-1120
Transmembrane domain	1121-1143
Cytosolic region	1144-1257
Mature L1 polypeptide	20-1257

**[0094]** Exemplary L1 polypeptide sequences are known. For example, L1 sequences are deposited as GenBank Accession Number NP\_000416.1 (incorporated by reference herein as present in the database on Jun. 20, 2013):

(SEQ ID NO: 1)

MVVALRYVWPLLCSPELLLIQIPEEYEGHHVMEPPVITEQSPRRLVVFPT  
 DDISLKCEASGKPEVQFRWTRDGVHFKPKBELGVTVYQSPHSGSFTITGN  
 NSNFAQRQFGIYRCFASNKLGKTAMSHIEIRLMAEGAPKWPKETVKPVEVEE  
 GESVVLPCNPPPSAEPLRIYWMNSKILHIKQDERVTMGQNGNLYFANVLT  
 SDNHSYDI CHAHFPGTRTI IQKEPIDLRVKATNSMIDRKPRLFPPTNSSS  
 HLVALQQQPLVLECI AEGFPPTPTIKWLRPSGMPADRVTYQNHKTLQLL  
 KVGEEDDGEYRCLAENSLGSRHAYVVTVEAAPYWLHKPQSHLYGPGETA  
 RLDCQVQGRPQPEVTWRINGI PVEELAKDQKYRIQRGALILSNVQPSDTM  
 VTQCEARNRHGLLLANAYI YVVQLPAKIL TADNQTYMAVQGSTAYLLCKA  
 FGAPVPSVQWLDEDGTTVLQDERFFPYANGTLGIRDQLQANDTGRYFCLAA  
 NDQNNVTIMANLKVKDATQITQGPRSTIEKKGSRVTFTCQASFDPQLQPS  
 ITWRGDGRDLQELGDSKDYFIEDGRLVIHSLDYSQGNYSVAVSTELDVV  
 ESRAQLLVVSGSPGPVRLVLSDLHLLTQSQVRVSWSPAEDHNAPIEKYDI  
 EFEDKEMAPEKWYSLGKVPGNQSTTLKLSPYVHYTFRVTAINKYGPGEF  
 SPVSETVVTPEAAPEKNPVDVKEGNETNMVITWKPLRWDWNAPQVQY  
 RVQWRPQGRGWQEQIVSDPFLVVSNTSTFVPEYIKVQAVNSQGGKPEP  
 QVTIGSYSGEDYPQAIPELEGIETLNS SAVLVKWRPVDLAQVKGHLRGYNV  
 TYWREGSQRKSKRHIHKDHVVVPANTTSVILSGLRPYSYHLEVQAFNG  
 RSGSPASEFTFSTPEGVPGHPEALHLECSNTSLLLRWQPPLSHNGVLTG  
 YVLSYHPLDEGGKQLS FNLRDPELRTHNLTDLSPHLRYRFQLQATTKEG  
 PGEAIVREGGTMALSGISDFGNI SATAGENYSVSWVPKQGCNFRPHIL  
 FKALGEEKGGASLSPQYVSYNQSSYTCQDWLQPDTDYIEIHLFKERMFRHQM  
 AVKNTNGTRVRLPPAGFATEGWFIGFVSAI ILLLLVLLILCFIKRSKGGK  
 YSVKDKEDTQVDS EARPMDKETFGEYRSLSDNEEKAFGSSQPSLNGDIK

- continued

PLGSDDSLADYGGSVQVDFNEDGSFIGQYSGKKEKEAAGNDSSGATSPI  
NPAVALE

**[0095]** Exemplary NCAM1 polypeptide sequences are known. For example, NCAM1 sequences are deposited as GenBank Accession Number BC047244.1 (incorporated by reference herein as present in the database on Jun. 20, 2013):

(SEQ ID NO: 2)  
MLQTKDLIWTFLFPLGTAVSLQVDIVPSQGEISVGESKFFLCQVAGDAKDK  
DISWFSPNGEKLTPNQRIISVVWDDSSSTLTIIYANIDDAIGYKCVVTVG  
EDGSESEATVNVKIFQKLMFNAPTQEFREGEDAVIVCDVSSLPTTII  
WKHKGRDVLKDKDVRFIVLSNNYLQIRGIKKTDEGTYRCEGRILARGEIN  
FKDIQVIVNVPTTIQARQNIIVNATANLQSVTLVCDABEGFPEPTMSWTKD  
GEQIEQEEDDEKYIFSDSSQLTIKKVDKNDAAEYICIAENKAGEQDATI  
HLKVFAPKPI TYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISS  
EEKASWTRPEKQETLDGHMVVRSHARVSSLTLSIQYTDAGEYICTASNT  
IGQDSQSMYLEVQYAPKLQGPVAVYTWEGNQVNI TCEVFAYPSATISWFR  
DGQLPSSNYSNIKIYNTPSASYLEVTPDSEDFGNYNCTAVNRIGQESL  
EFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPIILKYKAEWRAV  
GEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAA  
SEFKTQPVQGEPSAPKLEGMGEDGNSIKVNLIKQDDGGSPIRHVLRVYR  
ALSSEWKPEIRLPSGSDHVMLKSLDWNAAEYEVVVAENQQGKSKAAHFVF  
RTSAQPTAIPANGSPTSGLSTGAIVGILIVIFVLLLVVDITCYPLNCKG  
LFMCIAVNLCGKAGPGAKGDMEEGKAAPSKDESKEPIVEVTRTEERTPN  
HDGKHTEPNETTPLTEPEKGPVEAKPECEQETETKPAPAEVKTVPNDATQ  
TKENENKA

**[0096]** Exemplary CHCL1 polypeptide sequences are known. For example, CHCL1 sequences are deposited as GenBank Accession Number AAI43497 (incorporated by reference herein as present in the database on Jun. 20, 2013):

(SEQ ID NO: 3)  
MEPLLGRGLIVYLMFLLKFSKAIEIPSSVQQVPTIIKQSKVQVAFPPD  
EYFQIECEAKGNPEPTFSWTKDGNPFYFTDHRII PSNNSGTFRIPNEGHI  
SHFQGYKRCFASNKLGIAMSEIEFIVPSVPKFPKEDIPLVEBEGDPIV  
LPCNPPKGLPPLHIYWMNI ELEHIEQDERVYMSQKGDLYFANVEEKSRN  
DYCCFAAPRLRTIVQKMPKLTVNSSNSIKQRKPKLLLPPTESGSESSI  
TILKGEILLLECFAGEPLTPQVDWNKIGDLPKGREAKENYKTLKIENV  
SYQDKGNYRCASNFLGTATHDFHIVIEEPPRWTKKQSAVYSTGNGIL  
LCEAEGEPQPTIKWRVNGSPVDNHPFAGDVVFPREISFTNLQPNHTAVYQ  
CEASNVHGTLANANIDVVDVRLIQT KDGENYATVVGYSAPLHCFEFAS  
PEAVVSWQKVEEVKPLEGRRYHI YENGLQINRTTEEDAGSYSCWVENAI

- continued

GKTAVTANLDIRNATKLRVSPKNPRI PKLHMLELHCEKCDSHLKHSLKL  
SWSKDGAEFEINGTEDGRIIIDGANLTI SNVTLEDQGIYCCSAHTALDSA  
ADITQVTVLDVDPDENLHLSERQNRSVRLTWEAGADHNSNISEYIVEFE  
GNKEEPGRWEELTRVQGGKTTVILPLAPFVRYQFRVIAVNEVGRSQPSQP  
SDHHETPPAAPDRNPQNIRVQASQPKEMIIKWEPLKSMEQNGPGLERYVT  
WKPQGAPVEWEEETV TNHTLRVMTPAVYAPYDVVKVQAINQLGSGPDPQSV  
TLYSGEDYPTAPVIHGVDVINSTLVKVTWSTVTPKDRVHGRLLKGYQINWW  
KTKSLLDGRTHPKVNI LRFSGQRNSGMVPSLDAFSEFHLTVLAYNSKGA  
GPESEPYIFQTPPEGVPEQPTFLKVIKVDKDTATLSWGLPKKLNGLTGYL  
LQYQIINDTYEIGELNDINITTPSKPSWHLNLSNLTATKYKFLRACTSQG  
CGKPI TEESSTLGEKSGIKISGVNLTQKTHPVEVPEPGEHIVRLMTK  
NVVGDNDISIFQDVIETRGREYAGLYDDISTQGFWIFGLMCAIALLTLLLLT  
VCFVKNRGGKYSVKEKEDLHPDPEIQSVKDETFGEYSDSDEKPLKGLSLR  
SLNRDMQPTESADSLVEYEGEGDHGLFSEDSGFI GAYAGSKEKGSVESNGS  
STATFPLRA

**[0097]** Exemplary polypeptide sequences are known. For example, Neurofascin sequences are deposited as GenBank Accession Number 094856 (incorporated by reference herein as present in the database on Jun. 20, 2013):

(SEQ ID NO: 4)  
MARQPPPPVWHAFFLLCCLSLGGAIEIPMDPSIQNELTQPPTITKQSAKD  
HIVDPRDNI LIECEAKGNPAPSFHWTRNSRFFNIAKDPVSMRRRSGTLV  
IDFRSGGRPEEYEGEYQCFARNKFGTALS NRIRLQVSKSPLWPKENLDPV  
VVQEGAPLTLQCNPPGLPSPVIFWSSSMEPITQDKRVSQGHNGDLYFS  
NVMLQDMQTDYSCNARFHFHTHTIQQKNPFTLKVLTTRGVAERTPSFMYPQ  
GTASSQMVLRGMDLLECIASGVPTPIAWYKKGGLDPSDKAKFENFNKA  
LRITNVSEEDSGEYFCLASNKMGSI RHTISVRVKAAPYWLDEPKNLI LAP  
GEDGRLVCRANGNPKPTVQWVNGEPLQSAAPPNPNREVAGDTIIFRDTQI  
SSRAVYQCNTSNEHGYL LANAFVSVLDVPPRMLSPRNQLIRVILYNRTRL  
DCPPFGSPIPTLRWFKNQGSNLDGGNYHVYENGSL EIKMIRKEDQGIYT  
CVATNILGKAENQVRLEVKDPTRI YRMPEDQVARRGTTVQLECRVKHDP S  
LKLTVSWLKDDEPLYIGNRMKEDDSLIFGVAERDQGSYTCVASTELDQ  
DLAKAYLTVLADQATPTNRLAALPKGRPRDRDLELTDLAERSVRLTWIP  
GDANNSPI TDYVVQFEEQFQPGVWHDHSHKYPGSVNSAVLRLSPYVNYQF  
RVIAINEVGS SHPSLPSERYRTSGAPPESNPGDVKGEGTRKNMMEITWTP  
MNATSAGFPNLRIVKWRRRETREAWNNVTVWGSRYVVGQTPVYVPEYIR  
VQAENDFGKGPESVIGYSGEDYPRAAPTEVKVRVMNSTAISLQWNRVY  
SDTVQGLREYRAYWRESLLKNLWVSQKRQASFPGRDLRGVVSRLFP  
YSNYKLEMVVVNGRGGPRSETKEFTTPEGVPSAPRRFRVRQPNETINL  
EWDHPEHPNGIMIGYTLKYVAFNGTKVKGQIVENFSPNQTKFTVQRTDPV

- continued

SRYRFTLSARTQVGSGEAVTEES PAPPNEATPTAAPPTLPPTTVGATGAV  
 SSTDATAIAATTEATTVP I IPTVAPT I IATTTT VATT TTTTAAATTTTES  
 PPTTTS GTKI HESAPDEQS IWNVTVLPNSKWANI TWKHNFPGTDFVVEY  
 IDSNHTKKTVPVKAQAQPIQLTDLYPGMTYTLRVYSRDNEGISSTVITFM  
 TSTAYTNQADIATQGWFI GLMCAIAALLVLLILLIVCFIKRSGGKYPVRE  
 KKDVP L GPEDPKEEDGSFDYSDENKPLQGSQTS LDGTIKQQESDSDLVD  
 YGEGGEGQFNEDGSFIQGYTVKKDKEETEGNESSEATSPVNAIYSLA

**[0098]** One skilled in the art will appreciate that these sequences can be altered, while still retaining the desired function. Thus in some examples the sequences used have at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 1 (or SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4) or a portion thereof, such as the Ig1, Ig2, Ig3, or Ig4 domains (or all 4 of these domains), the extracellular domain, or the mature L1 polypeptide. In some embodiments, the L1 polypeptide or functional fragment thereof includes or consists of the amino sequence set forth as SEQ ID NO: 1 or amino acids 20-1120 of SEQ ID NO: 1, or an amino acid sequence including at least 85% (such as at least 90%, 95%, 96%, 97%, 98, or 99%) sequence identity to the amino acid sequence set forth as SEQ ID NO: 1 or amino acids 20-1120 of SEQ ID NO: 1.

**[0099]** It is understood in the art that some variations can be made in the amino acid sequence of a protein without affecting the activity of the protein. Such variations include insertion of amino acid residues, deletions of amino acid residues, and substitutions of amino acid residues. These variations in sequence can be naturally occurring variations or they can be engineered through the use of genetic engineering techniques known to those skilled in the art. Examples of such techniques are found in Sambrook J, Fritsch E F, Maniatis T et al., in *Molecular Cloning—A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, pp. 9.31-9.57), or in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, both of which are incorporated herein by reference in their entirety. Thus, in additional embodiments, the L1 polypeptide includes one or more amino acid substitutions compared to the native L1 polypeptide (such as the polypeptide sequence set forth as SEQ ID NO: 1). For example, in some embodiments, the L1 polypeptide includes up to 20 amino acid substitutions compared to the native L1 polypeptide sequence.

**[0100]** In some embodiments, NCAM or functional fragment thereof is linked to an electrode. NCAM has similar (but distinct) cell adhesive activity as L1. Purification of NCAM is described in Lagenaur, C., Yip, j., and Lemmon, V. (1988) "Monoclonal 12F8 antibody identifies a subclass of N-CAM active in promotion of neurite outgrowth. *Soc. Neurosci. Abstr.* 14, 2253. The GenBank Accession number for human NCAM is AAH47244.1. In some embodiments, the NCAM polypeptide includes or consists of the amino sequence set forth as SEQ ID NO: 1, or an amino acid sequence including at least 85% (such as at least 90% or 95%) sequence identity to the amino acid sequence set forth as SEQ ID NO: 1.

**[0101]** Standard methods in the art can be used to produce the L1 polypeptide or functional fragment thereof or variant or homologue thereof. For example, recombinant DNA technology can be used to generate a nucleic acid encoding the L1

polypeptide, from which the peptide can be expressed and purified. Typically, the nucleic acid encoding the L1 polypeptide is expressed in eukaryotic cells.

**[0102]** In some embodiments the L1 polypeptide is purified from neural tissue (e.g., brain tissue) using immunoaffinity chromatography, for example, as described in Lagenaur and Lemmon, V, *An L1-like molecule, the 8D9 antigen is a potent substrate for neurite extension*. *Proc. Natl. Acad. Sci. USA*, 1987, 84: p. 7753-7757, the disclosure of which is incorporated by reference herein in its entirety. The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified L1 polypeptide preparation is one in which the L1 polypeptide is more enriched than the L1 polypeptide is in its natural environment within a cell. In one embodiment, a L1 polypeptide preparation is purified such that the L1 polypeptide represents at least 50% (such as at least 60, 70, 80, or 90%) of the total polypeptide content of the preparation.

**[0103]** A polypeptide is a polymer of amino acid residues that are joined together through amide bonds. The amino acids included in a polypeptide can be subject to post-translational modification (e.g., glycosylation, sulfation or phosphorylation), and "polypeptide" applies to amino acid polymers including naturally occurring amino acid polymers and non-naturally occurring amino acid polymer as well as in which one or more amino acid residue is a non-natural amino acid, for example an artificial chemical mimetic of a corresponding naturally occurring amino acid. A "residue" refers to an amino acid or amino acid mimetic incorporated in a polypeptide by an amide bond or amide bond mimetic. A polypeptide has an amino terminal (N-terminal) end and a carboxy terminal (C-terminal) end.

**[0104]** In other embodiments, the L1 polypeptide or functional fragment can be produced using recombinant DNA methodologies, e.g., by expressing a nucleic acid molecule encoding a recombinant L1 polypeptide in a host cell, and purifying the L1 polypeptide. Nucleic acid molecules encoding the L1 polypeptide or a fragment thereof provided herein can readily be produced by one of skill in the art. For example, these nucleic acids can be produced using the amino acid sequences provided herein, sequences available in the art, and the genetic code. L1 polypeptides and functional fragment thereof are provided above. One of skill in the art can readily use the genetic code to construct a variety of nucleic acid molecules encoding the L1 polypeptide or a fragment thereof, including functionally equivalent nucleic acids, such as nucleic acids which differ in sequence but which encode the same polypeptide, or encode a fusion protein including the polypeptide and another protein.

**[0105]** Nucleic acid sequences encoding the L1 polypeptide or functional fragment thereof can be prepared by any suitable method including, for example, cloning of appropriate sequences or by direct chemical synthesis by methods such as the phosphotriester method of Narang et al., *Meth. Enzymol.* 68:90-99, 1979; the phosphodiester method of Brown et al., *Meth. Enzymol.* 68:109-151, 1979; the diethylphosphoramidite method of Beaucage et al., *Tetra. Lett.* 22:1859-1862, 1981; the solid phase phosphoramidite triester method described by Beaucage & Caruthers, *Tetra. Letts.* 22(20):1859-1862, 1981, for example, using an automated synthesizer as described in, for example, Needham-VanDevanter et al., *Nucl. Acids Res.* 12:6159-6168, 1984; and, the solid support method of U.S. Pat. No. 4,458,066. Chemical synthesis produces a single stranded oligonucleotide. This

can be converted into double stranded DNA by hybridization with a complementary sequence or by polymerization with a DNA polymerase using the single strand as a template. One of skill would recognize that while chemical synthesis of DNA is generally limited to sequences of about 500 bases, longer sequences can be obtained by the ligation of shorter sequences.

**[0106]** Exemplary nucleic acids can be prepared by cloning techniques. Examples of appropriate cloning and sequencing techniques, and instructions sufficient to direct persons of skill through many cloning exercises are found in Sambrook et al., supra, Berger and Kimmel (eds.), supra, and Ausubel, supra. Product information from manufacturers of biological reagents and experimental equipment also provide useful information. Such manufacturers include the SIGMA Chemical Company (Saint Louis, Mo.), R&D Systems (Minneapolis, Minn.), Pharmacia Amersham (Piscataway, N.J.), CLONTECH Laboratories, Inc. (Palo Alto, Calif.), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, Wis.), Glen Research, Inc., GIBCO BRL Life Technologies, Inc. (Gaithersburg, Md.), Fluka Chemica-Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), Invitrogen (Carlsbad, Calif.), and Applied Biosystems (Foster City, Calif.), as well as many other commercial sources known to one of skill.

**[0107]** Nucleic acids can also be prepared by amplification methods. Amplification methods include polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (3SR). A wide variety of cloning methods, host cells, and in vitro amplification methodologies are well known to persons of skill.

**[0108]** Any of the nucleic acids encoding any of the polypeptides disclosed herein (or fragment thereof) can be expressed in a recombinantly engineered cell such as bacteria, plant, yeast, insect and mammalian cells. In some embodiments, the polypeptides can be expressed as a fusion protein. The nucleic acid sequences can optionally encode a leader sequence.

**[0109]** It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of proteins including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO, HeLa and myeloma cell lines.

**[0110]** One or more DNA sequences encoding the disclosed L1 polypeptide or functional fragment thereof can be expressed in vitro by DNA transfer into a suitable host cell. The cell may be prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.

**[0111]** The expression of nucleic acids encoding the L1 polypeptide or functional fragment thereof can be achieved by operably linking the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression cassette. The promoter can be any promoter of interest, such as a cytomegalovirus promoter. Optionally, an enhancer, such as a cytomegalovirus enhancer, is included in the construct. The cassettes can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression cassettes contain specific sequences useful for regulation of the expression of the DNA encoding the protein. For example, the expression cassettes can include

appropriate promoters, enhancers, transcription and translation terminators, initiation sequences, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signal for introns, sequences for the maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons. The vector can encode a selectable marker, such as a marker encoding drug resistance (for example, ampicillin or tetracycline resistance).

**[0112]** Modifications can be made to a nucleic acid encoding a polypeptide described herein without diminishing its biological activity. Some modifications can be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, termination codons, a methionine added at the amino terminus to provide an initiation site, additional amino acids placed on either terminus to create conveniently located restriction sites, or additional amino acids (such as poly His) to aid in purification steps.

**[0113]** Once expressed, the polypeptides can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, and the like (see, generally, R. Scopes, PROTEIN PURIFICATION, Springer-Verlag, N.Y., 1982). The polypeptides need not be 100% pure. Once purified, partially or to homogeneity as desired, if to be used therapeutically, the polypeptides should be substantially free of endotoxin.

**[0114]** Methods for expression of polypeptides and/or refolding to an appropriate active form, from bacteria such as *E. coli* have been described and are well-known and are applicable to the antibodies disclosed herein. See, Buchner et al., *Anal. Biochem.* 205:263-270, 1992; Pluckthun, *Biotechnology* 9:545, 1991; Huse et al., *Science* 246:1275, 1989 and Ward et al., *Nature* 341:544, 1989.

#### D. Polypeptide Conjugation

**[0115]** In several embodiments, an effective amount of L1 polypeptide or functional fragment thereof can be conjugated to the exterior surface of a neural probes for recording and/or stimulating a neural signal, for example by conjugation to the exterior surface of the insulating layer included on the neural probe. In some embodiments, the probe includes a parylene C insulating layer on its exterior surface, and the L1 polypeptide or functional fragment thereof is conjugated to the exterior surface of the parylene C insulating layer. Methods of conjugating (e.g., covalently bonding one molecule to another) a polypeptide to the surface of a neural probe, or the surface of an insulating layer (such as an insulating layer including parylene C) are known in the art, and are further described herein.

**[0116]** For example, for probes including a silicon oxide insulation layer on their exterior surface, silane chemistry and a GMBS crosslinker may be used to covalently attach the L1 polypeptide or functional fragment thereof to the exterior of the insulation layer (see, e.g., Azemi et al., *Acta Biomaterialia*, 2008, 4(5): p. 1208-1217, which is incorporated by reference herein).

**[0117]** Additionally, several coating strategies to immobilize proteins on a parylene C surface have been developed. A first approach utilizes air plasma to modify the parylene C surface with polar hydroxyl groups at the surface (see, e.g., Chang et al., *Langmuir*, 2007, 23(23): p. 11718-25; and Sia and Whitesides, *Electrophoresis*, 2003, 24(21): p. 3563-76, each of which is incorporated by reference herein in its

entirety). The probes are then soaked in a protein solution containing the L1 polypeptide or functional fragment thereof (e.g., a solution with 50-150  $\mu\text{g}/\text{mL}$  L1) for about 1 hour. The successful attachment of the desired protein may be characterized using known methods, for example immunostaining and the bioactivity of the bound protein can be verified in cell culture (see, e.g., Kolarcik et al., *Acta Biomater*, 2012, 8(10): p. 3561-75, which is incorporated by reference herein in its entirety).

**[0118]** Additional methods have also been developed for conjugation of proteins to parylene C surfaces. For example, surface treatment of a parylene C coated neural probe with succinic anhydride adds carboxylic acid groups on the exterior surface of the probe, which can then react with amine on proteins (see, e.g., FIG. 15E) (see, e.g., Zhang et al., *Acta Biomater*, 2011, 7(10): p. 3746-56, which is incorporated by reference herein in its entirety). Another method involves the synthesis of diamino(2,2)paracyclophane by nitration of (2,2)paracyclophane and subsequent reduction of the nitro groups. The diamino(2,2)paracyclophane can then form a parylene coating in a CVD chamber which has amine groups available for protein binding (see FIG. 2F; and Lahann et al., *Angew Chem Int Ed Engl*, 2001, 40(16): p. 2947, which is incorporated by reference herein in its entirety).

**[0119]** In some embodiments, the L1 polypeptide or functional fragment thereof can be conjugated to a conductive surface of an electrode included on the neural probe, such as an exterior surface of the electrode, for example to promote neuronal attachment as close as possible to the conductive surface of the electrode. For example, the L1 polypeptide may be conjugated to the conductive surface of the electrode using direct co-deposition of conducting polymer and L1 on conductive sites on the electrode (see, FIGS. 16A-16B). In further embodiments, L1 polypeptide can be conjugated to the conductive surface of the electrode using polyethylenedioxythiophene (PEDOT) doped with graphene oxide (GO), which can then be covalently linked to protein via carboxylic acid groups on GO (see FIGS. 16C-16D). Methods of conjugating polypeptides to conductive surfaces of an electrode are described, e.g., in Luo et al., *J Mat. Chem. B*, 2013, 1(1): p. 1340-1348, which is incorporated by reference herein in its entirety.

**[0120]** In additional embodiments, the L1 polypeptide or functional fragment can be covalently attached to the carboxyl functional groups of poly(acrylic acid) (PAA) and lightly cross-linked (e.g., with EDC chemistry), resulting in a stable and soluble L1-polymer conjugate. For silicon oxide substrates, the L1-polymer conjugate can then be covalently attached to the silicon oxide surface using traditional silanization/GMBS methods as described herein. For parylene C substrates, the L1-polymer conjugate can be conjugated to a parylene C coated probe after that probe is treated with plasma oxygen (as described herein), or crosslinked to the exterior surface of a parylene C coated probe via EDC/NHS cross-linking after that probe is treated with plasma oxygen.

**[0121]** The probes and devices can be stored before use as needed. In some embodiments, a probe or device including an L1 polypeptide or functional fragment thereof on its exterior surface can be freeze-dried following conjugation of the L1 polypeptide or functional fragment to increase storage shelf-life. The probe can then be maintained at freezing temperatures (e.g.,  $-20^{\circ}\text{C}$ .) in the presence of desiccant as needed, after which the probe can be rehydrated with sterile PBS prior to use. In additional embodiments, prior to freeze-drying,

probe can be treated with a cross-linking agent (e.g., free radical oxidation using superoxide), to crosslink L1 polypeptide or the functional fragment thereof, to increase the stability (and shelf-life) of the L1 polypeptide or functional fragment.

**[0122]** In additional embodiments, a protective coating composed of layer-by-layer-deposited mannitol and polyelectrolytes can be used to seal the prepared L1-coated probe to improve stability prior to storage (or freeze-drying). Stored L1 coated probes can then be rehydrated with sterile PBS to dissolve the protective coating. Alternatively, polyethylene glycol gel may be applied to preserve the bioactivity of the underlying protein upon freeze-drying and storage.

#### E. Recording and/or Stimulating Neural Signals

**[0123]** In several embodiments, a disclosed probe (or device including the probe) can be used for chronic recording and/or stimulation of neural signals from a subject. For example the probe (or device including the probe) can be implanted into neuronal tissue of the subject, and used to record and/or stimulate neural signals from the subject for a period of at least 1 month (such as at least 2, 6, 12, 18, 24, 30 or 36 or more months) without deterioration of quality or quantity of the recorded or stimulated neural signal. In several such embodiments the probe includes a parylene C insulating layer, the exterior surface of which is conjugated to an L1 polypeptide or functional fragment thereof as disclosed herein.

**[0124]** Methods and systems for implanting probes into neuronal tissue of a subject (e.g., central neuronal tissue such as the brain or spinal cord, or peripheral neuronal tissue, such as the dorsal root ganglia) are known to the person of ordinary skill in the art, and further described herein. Further, methods and systems for recording and/or stimulating neural signals from an probe implanted in neuronal tissue in a subject are known.

**[0125]** As illustrated herein, using neural probes that lack L1, a recording increase (quality and yield) is expected over the first few weeks after the probe is implanted into neuronal tissue of a subject. Without being bound by theory, this initial increase (lasting a few weeks) is believed to be due to recovery of tissue from insertion trauma. After the initial increase the recording quality stabilizes and eventually begins to decrease at longer time points. In contrast, using the disclosed probes that include an effective amount of L1 polypeptide or functional fragment thereof on their exterior surface, an increase in neural signal that continues for several months (e.g., at least 2 (such as at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 24, 30, 36, or more months) was recorded. Furthermore, using probes including the L1 or functional fragment, an increased number of sortable units per channel and higher amplitude of signal is possible compared to probes without L1.

**[0126]** In some embodiments use of the disclosed probe (or device including the probe) allows for an increase in the recorded neural signal over time. For example, in some embodiments, use of the disclosed probe (or device including the probe) allows for an increase in the total number of sortable neural units over time; for example, an increase of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or more of an increase in total number of sortable neural recording units over time. In some embodiments, use of the disclosed probe (or device including the probe) allows for an increase in the average number of sortable neural units per channel of the probe over time; for example, an increase of at



least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or more of an increase in the average number of sortable neural recording units per channel of the probe over time. In some embodiments the increase over time is measured at 4 weeks post implantation compared to 20 weeks post implantation.

**[0127]** Methods of identifying neural recording units in data recorded from an electrode (or array of electrodes) implanted in a subject are known to the person of ordinary skill in the art (see, e.g., Lewicki, "A review of methods for spike sorting: the detection and classification of neural action potentials," *Network: Comput. Neural Syst.*, 9, R53-R78, 1998, which is incorporated by reference herein in its entirety). In some embodiments, raw neural recording data is first band passed filtered between 300 Hz to 10 kHz. Following data filtering, waveforms that cross the TDT automatic threshold are selected for further spike sorting analysis. Hoop-based spike discrimination is carried out online as the experimenter selects time-voltage windows based on waveform shape. Waveforms that fall within this selected window are classified as belonging to the same sort. Manual inspection of the sorted units in principal component analysis space is used to assess the appropriateness of the selected windows. Online spike sorting progresses by relying upon template matching to properly sort units that fall into one of the above mentioned time-voltage windows.

**[0128]** The probe and/or device is typically linked to circuitry for recording and/or stimulating a neural signal via the one or more electrodes included on the probe. The person of ordinary skill in the art is familiar with circuitry for use with the disclosed devices. In some embodiments, the integrated circuits can be fully implanted (typically implantable in a subcutaneous pocket within a patient's body) or partially implanted in the patient, but are not limited thereto. The operable linkage to the probe or device can be by way of one or more leads, although any operable linkage capable of transmitting the measured neural signal from the electrodes to the circuitry, or a stimulation signal from the circuitry to the electrodes, can be used.

**[0129]** In some embodiments, the integrated circuitry includes a stimulator linked to the device and suitably designed for application of various current, voltage, pulse rate, waveforms etc., for generating a neural signal in one or more neurons in proximity to the electrode or electrodes included on the device. For example, the stimulator can be separate from the integrated circuitry or it can be included in the same housing as the integrated circuitry.

#### EXAMPLES

**[0130]** The following examples are provided to illustrate particular features of certain embodiments, but the scope of the claims should not be limited to those features exemplified.

##### Example 1

##### In Vivo Effects of L1 Coating on Inflammation and Neuronal Health at the Electrode/Tissue Interface in Rat Spinal Cord and DRG

**[0131]** The example illustrates use of L1 coated neural probes for improved recording of neural signals over time.

**[0132]** Abstract.

**[0133]** The spinal cord and dorsal root ganglion (DRG) are target implantation regions for neural prosthetics, but the

tissue-electrode interface in these regions is not well-studied. To improve understanding of these locations, the tissue reactions around implanted electrodes were characterized. L1, an adhesion molecule shown to maintain neuronal density and reduce gliosis in brain tissue, was evaluated in spinal cord and DRG implants. Following L1 immobilization onto neural probes, the bioactivities of the coatings were verified in vitro using neuron, astrocyte and microglia cultures. Non-modified and L1-coated probes were implanted into adult rats for 1 or 4 weeks. Hematoxylin and eosin staining along with cell-type specific antibodies were used to characterize the tissue response. In the spinal cord and DRG, cells aggregated at the electrode-tissue interface. Microglia staining was more intense around the implant site and decreased with distance from the interface. Neurofilament staining in both locations was decreased or absent around the implant when compared to surrounding tissue. With L1, neurofilament staining was significantly increased while neuronal cell death decreased. The results indicate that L1-modified probes may result in an improved chronic neural interface and will be evaluated in recording and stimulation studies.

**[0134]** Introduction.

**[0135]** Neural prosthetic devices implanted into the nervous system to bypass and/or restore sensory-motor or cognitive functions have enormous clinical potential. There are a variety of situations in which such devices can be of use with proposed applications in the fields of gerontology, rehabilitative medicine, psychiatry, neurology and clinical research (Rothschild, *Front Neuroeng*, 3:112, 2010). More specifically, neural interface systems (NIS) can be used for communication (Ryu and Shenoy, *Neurosurg Focus*, 27:E5, 2009), to restore lost functional movement (Song et al., *Conf Proc IEEE Eng Med Biol Soc*, 2007:445-8, 2007), to reinnervate target locations for bladder control and for the treatment of neurological conditions like epilepsy (Morrell, *Curr Opin Neurol*, 19:164-8, 2006; Skarpaas and Morrell, *Neurotherapeutics*, 6:238-43, 2009) and Parkinson's Disease (Pena et al., *IEEE Trans Neural Syst Rehabil Eng*, 15:421-4, 2007) among others. While much effort has been devoted to brain interfaces, both the spinal cord and DRG are target implantation regions for these promising rehabilitative and therapeutic devices as well. For example, spinal cord stimulation has been investigated for pain control (Waltz, *Stereotact Funct Neurosurg*, 69:288-99, 1997) and restoration of motor functions (Mushahwar et al., *IEEE Trans Neural Syst Rehabil Eng*, 10:68-81, 2002; Moritz et al., *J Neurophysiol*, 97:110-20, 2007), while the DRG is an attractive site for recording or stimulating primary afferent neurons to provide sensory feedback (Weber et al., *J Neural Eng*, 4:S168-80, 2007; Gaunt et al., *J Neural Eng*, 6:055009, 2009).

**[0136]** Irrespective of the implant location, these neural interfaces must remain stable throughout the lifespan of the user. However, biocompatibility issues have limited the success of chronically implanted devices (Schwartz, *Annu Rev Neurosci*, 27:487-507, 2004; Schwartz et al., *Neuron*, 52:205-20, 2006; Cheung, *Biomed Microdevices*, 9:923-38, 2007; Polikov et al., *J Neurosci Methods*, 148:1-18, 2005). The fate of implanted devices is often determined by the effective integration with the surrounding neural tissue, a current and major roadblock in neuroengineering (Rothschild, *Front Neuroeng*, 3:112, 2010; Rao and Winter, *Front Neuroeng*, 2:6, 2009; Straley and Heilshorn, *Front Neuroeng*, 2:9, 2009; Grill et al., *Annu Rev Biomed Eng*, 11:1-24, 2009). In brain tissue, immune and inflammatory reactions including gliosis at the

implant site result in decreased performance of microelectrodes. Gliosis is thought to be mediated by macrophages, activated microglia and reactive astrocytes resulting in the formation of a glial sheath that can encapsulate and isolate the implanted probe from the surrounding tissue (Azemi et al., *Acta Biomater*, 4:1208-17, 2008). In addition, significant decreases in neuronal density in the area immediately surrounding the implant site (the “kill zone”) are problematic. In the peripheral system, manipulation or damage to a neural structure also leads to anatomic, metabolic and physiological alterations (Panetsos et al., *IEEE Trans Neural Syst Rehabil Eng*, 16:223-32, 2008). However, the reactions surrounding these peripheral interfaces highlight the potential for nerve regeneration and recovery following initial damage (Panetsos et al., *IEEE Trans Neural Syst Rehabil Eng*, 16:223-32, 2008; Pardue et al., *Exp Eye Res*, 73:333-43, 2001; Lago et al., *IEEE Trans Biomed Eng*, 54:1129-37, 2007). Although valuable for multiple applications, the spinal cord and DRG are less well-studied than the brain and peripheral nerve.

**[0137]** Surface modifications of implanted electrodes are one approach used to promote favorable interactions between the neural implants and neural cells, and a variety of biomaterial designs have been investigated (Ryu and Shenoy, *Neurosurg Focus*, 27:E5, 2009; Rao and Winter, *Front Neuroeng*, 2:6, 2009). L1, a transmembrane cell surface glycoprotein, mediates cell-cell recognition by interacting with L1 molecules on the surfaces of neighboring cells (“hemophilic interactions”) or with non-L1 molecules on the surfaces of these cells (“heterophilic interactions”) (Maness and Schachner, *Nat Neurosci*, 10:19-26, 2007; Figge et al., *Mol Cell Neurosci*, 49:196-204, 2011). It is one of the molecular cues that promotes neurite outgrowth (Lemmon et al., *Neuron*, 2:1597-603, 1989; Lagenaur and Lemmon, *Proc Natl Acad Sci USA*, 84:7753-7, 1987) thereby contributing to the formation of the complex neuronal connections of the nervous system (Figge et al., *Mol Cell Neurosci*, 49:196-204, 2011). It is also involved in neuronal migration and synaptic plasticity with essential roles in the maintenance of nervous system functions (Maness and Schachner, *Nat Neurosci*, 10:19-26, 2007; Kenwrick et al., *Hum Mol Genet*, 9:879-86, 2000).

#### Materials and Methods

**[0138]** Neural Probes and Surface Modification.

**[0139]** Standard tip tungsten microelectrodes (Micro-Probes, Gaithersburg, Md.) were used for both in vitro experiments and in vivo implants. Each microelectrode was cut to a 3 mm length for chronic insertion into the neural tissue. The shaft diameter of these tips was approximately 0.081 mm (with a parylene-C coating of 3  $\mu\text{m}$ ) and an exposed tip diameter of 1-2  $\mu\text{m}$  (25:1 taper).

**[0140]** L1 protein was purified from brain tissue as described previously (Azemi et al., *Acta Biomater*, 4:1208-17, 2008; Lagenaur and Lemmon, *Proc Natl Acad Sci USA*, 84:7753-7, 1987, each of which is incorporated by reference herein in its entirety) and concentrations determined using the FluoroProfile (Sigma-Aldrich, St. Louis, Mo.) epicoccone-based reagent kit (Mackintosh et al., *Proteomics*, 5:4673-7, 2005) using bovine serum albumin (BSA; Sigma-Aldrich) standards. All coating experiments were carried out in a sterile environment at room temperature. A two-step approach similar to that used by Musalla and colleagues was utilized (Musallam et al., *J Neurosci Methods*, 160:122-7, 2007). More specifically, parylene-C-insulated microwires

were treated with plasma for 10 seconds. Then two different protein solutions, L1 (100  $\mu\text{g}/\text{mL}$ ) or laminin (40  $\mu\text{g}/\text{mL}$ , Sigma-Aldrich), were added onto the parylene-C/plasma-modified surfaces for 1 hour at 4° C. The coating conditions included the following: 1.) untreated parylene-C, 2.) parylene-C+plasma treatment, 3.) parylene-C+plasma treatment+L1 and 4.) parylene-C+plasma treatment+laminin.

**[0141]** Neural probes for the in vivo studies were sterilized with ethylene oxide (EtO). The L1 group was treated with plasma for 10 seconds on each side and L1 deposited as described above for 1 hour at 4° C. The resulting L1-immobilized probes were rinsed with phosphate buffered saline (PBS, pH 7.4) and stored at 4° C. in sterile PBS until implantation. The L1 coating was performed the same day of the implantation.

**[0142]** Cell Culture.

**[0143]** L1 immobilization was confirmed by staining with the 5H7 L1 monoclonal primary antibody and fluorophore-conjugated secondary antibody as described (Azemi et al., *Acta Biomater*, 4:1208-17, 2008). The stability of the coatings was tested at two time points. For the day 0 time point, cells were plated on the same day as the coating was applied. For the day 5 time point, cells were added to the coated surface 5 days after the coating had been soaked in Dulbecco’s Modified Eagle Medium (DMEM) without serum at 37° C. and 5% CO<sub>2</sub>.

**[0144]** Rat cortices from embryonic day 18 (E18) Sprague-Dawley rats were obtained from BrainBits, LLC (Springfield, Ill.) and neuronal cultures prepared as described by Brewer and colleagues (Brewer, *J Neurosci Res*, 42:674-83, 1995). Cells were resuspended in neurobasal base media (Invitrogen, Carlsbad, Calif.) supplemented with B27 (Invitrogen), glutamine (Sigma-Aldrich) and glutamate (Sigma-Aldrich). Cells were plated on surface-modified parylene-C at a density of  $1.5 \times 10^5$  cells/cm<sup>2</sup> and maintained in culture for 3 days at 37° C. and 5% CO<sub>2</sub>.

**[0145]** Astrocyte-enriched cultures were prepared as described previously (Azemi et al., *Acta Biomater*, 4:1208-17, 2008). Briefly, rat cortices were digested with trypsin and the resulting cell suspension maintained in DMEM (Invitrogen) supplemented with 10% fetal calf serum (FCS; Thermo Scientific, Pittsburgh, Pa.) at 37° C. and 5% CO<sub>2</sub>. Glial cells were passaged weekly for up to 4 weeks. For surface modification experiments, glial cells were trypsinized, resuspended in DMEM/10% FCS and plated at a density of  $1.5 \times 10^5$  cells/cm<sup>2</sup>. Astrocytes were subsequently cultured for 2 days prior to fixation.

**[0146]** Highly Aggressively Proliferating Immortalized (HAPI) cells (Cheepsunthorn et al., *Glia*, 35:53-62, 2001) were kindly provided by Dr. Xiaoming Hu, Department of Neurology, University of Pittsburgh and cultured as described previously (Luo et al., *Biomaterials*, 32:6316-23, 2011). Briefly, HAPI cells were maintained in DMEM/F12 lacking HEPES and Phenol Red (Invitrogen) supplemented with L-glutamine (Sigma-Aldrich) and 10% fetal bovine serum (FBS; Thermo Scientific). After thawing, cells were passaged once prior to plating at a density of  $1 \times 10^5$  cells/cm<sup>2</sup> and incubated for 24 hours at 37° C. and 5% CO<sub>2</sub> before fixation.

**[0147]** Prior to immunohistochemical labeling, cells were fixed with 4% paraformaldehyde (PFA; Sigma-Aldrich) for 10 minutes. After blocking for 45 minutes with 4% goat serum in phosphate buffered saline (PBS), monoclonal antibodies for neuronal class III  $\beta$ -tubulin (2  $\mu\text{g}/\text{mL}$ ; Invitrogen), glial fibrillary acidic protein (0.4  $\mu\text{g}/\text{mL}$ ; GFAP; DakoCyto-

mation, Carpinteria, Calif.) and ED1 (4  $\mu\text{g}/\text{mL}$ ; Fisher Scientific, Pittsburgh, Pa.) were added for 1 hour at room temperature. After washing with PBS, fluorescence-conjugated secondary antibodies were added for 1 hour. Cell nuclei were stained with Hoechst 33258 (2  $\mu\text{g}/\text{mL}$ ; Sigma-Aldrich) in PBS. Ten samples for each coating condition were used for each experiment and experiments were repeated at least three times.

**[0148]** Digital images of the stained cells were taken using a fluorescence microscope (Zeiss Axioskop, Zeiss, USA). Neuronal attachment was determined by counting the number of neurons that showed co-localization of class III  $\beta$ -tubulin and Hoescht and had at least one neurite longer than the cell body dimensions. Astrocyte attachment was determined for cells that showed co-localization of GFAP and Hoescht. Microglia attachment was determined by the co-localization of ED1 and Hoescht. The entire probe was imaged and all cells on the surface of the probes were counted by a non-objective examiner. The cell number was reported by dividing the total number of cells by the projected surface area. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, Calif.). Comparisons involving multiple groups were accomplished using two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc analysis. A p value  $\leq 0.05$  was considered statistically significant.

**[0149]** Surgical Procedure.

**[0150]** All surgical procedures were done in accordance with those outlined by the United States Department of Agriculture and approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Animals were housed in the facilities of the University of Pittsburgh Department of Laboratory Animal Resources and given free access to food and water.

**[0151]** Twenty-four adult male Sprague-Dawley rats (300 $\pm$ 50 g) were used throughout this study. Three or four animals per time point were implanted in the spinal cord and/or DRG with either non-modified or L1-coated micro-electrode tips (outlined in Table 2). Both 1 week and 4 week time points were investigated in an effort to characterize the acute (1 week) and chronic (4 weeks) tissue responses.

**[0152]** Animals were anesthetized with 2.5% isofluorane in oxygen at 1 L/min for 5 minutes prior to surgery and then maintained for the duration of the procedure with 1-2% isofluorane. Anesthesia level was closely monitored during the procedure by observing changes in respiratory rate, heart rate, body temperature and absence of the pedal reflex. Ophthalmic ointment was applied to the eyes while animals were under anesthesia.

**[0153]** Animals were placed in a stereotaxic frame and the hair over the incision site removed. The skin was disinfected with isopropyl alcohol and betadine and a sterile environment maintained throughout the procedure. The lumbar spine was exposed through a dorsal midline incision using surgical elevators to clear soft tissue from bone. A unilateral laminectomy exposed the left side of the lumbar spinal cord and DRG. Every attempt was made to minimize removal and/or cutting of muscles and bone surrounding the area of implant. Once exposed, non-modified or L1-coated probes (~3 mm length) were inserted (1-4/spinal cord and 1-2/DRG) under a surgical microscope using a micromanipulator equipped with a vacuum tool; probes were held in place with the vacuum tool, positioned by moving the micromanipulator and then lowered into place. After the muscle and skin were sutured, the

animal recovered under close supervision in the surgical procedure room. Rats were monitored closely for signs of pain or distress and post-operative pain managed with buprenorphine (0.3 mg/kg). The same surgeon performed all surgeries to minimize variability associated with the surgery and probe implantation.

**[0154]** Tissue Preparation and Immunofluorescence.

**[0155]** At the designated time points, animals were anesthetized with a ketamine/xylazine cocktail (100/20 mg/kg) via the intraperitoneal (IP) cavity. Animals were then transcardially perfused with cold (4 $^{\circ}$  C.) PBS followed by 4% (w/v) PFA in PBS. The spinal cord/DRG tissue was removed, post-fixed for up to 3 days and then equilibrated in 30% sucrose. Dissected tissue was then cryoprotected using the optimal cutting temperature (OCT) compound (Tissue-Tek, Torrance, Calif.). Serial sections were cut at a 10  $\mu\text{m}$  thickness.

**[0156]** Monoclonal antibodies were used to detect neurofilament 200 kD (NF200; Millipore, Billerica, Mass.), vimentin (Clone V-9; Millipore) and neuronal nuclei (NeuN; Millipore). Polyclonal antibodies were used to detect Iba1 (Wako Chemicals USA, Inc., Richmond, Va.), glial fibrillary acidic protein (GFAP; DakoCytomation) and cleaved caspase-3 (Asp175; Cell Signaling Technology, Boston, Mass.). These antibodies were used at a dilution of 1:500 (NF200, Iba1, Vimentin, GFAP, NeuN) or 1:50 (cleaved caspase-3) and the appropriate fluorescence-conjugated antibody used at a dilution of 1:500.

**[0157]** Tissue sections were stained at the same time for each antibody/antibody pair to minimize variability. Hematoxylin and eosin (H and E) staining along with markers to visualize mature axons (NF200), microglia (Iba1), astrocytes/fibroblasts/endothelial cells (vimentin), astrocytes (GFAP), neuronal nuclei (NeuN) and cell death (cleaved caspase-3) (antibodies outlined in Table 3) were used.

**[0158]** Tissue sections were hydrated in PBS and non-specific binding blocked with 0.5% BSA. Primary antibodies were then diluted in BSA and added for approximately 1 hour. After washing with BSA, fluorophore-conjugated secondary antibodies (goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594) diluted in BSA were added for approximately 1 hour and Hoescht used as the nuclear stain. Fluoromount-G (Southern Biotechnology Associates, Birmingham, Ala.) was used for mounting and to preserve fluorescence. Negative controls lacking primary antibody were included for each secondary antibody.

**[0159]** Quantitative Tissue and Statistical Analyses.

**[0160]** Confocal fluorescent microscopy was used to evaluate the cellular reactions associated with the implanted probes. Images were acquired using an Olympus Fluoview 1000 I Confocal Microscope (Olympus America, Center Valley, Pa.) at the Center for Biologic Imaging at the University of Pittsburgh. For each antibody, images were acquired using the same exposure time and in a single session to reduce variability during data analysis. Images were centered on the implant site and multiple images acquired. Images were also taken at a significant distance from the implant and used to define the average background staining intensities for each stain on every tissue sample.

**[0161]** For quantification of NF200 staining, custom MATLAB software (MathWorks, Boston, Mass.) was used to determine the size of the kill zone. More specifically, the perimeter of each implant site was defined using the corresponding DAPI-stained image and the NF200-stained image

used to identify the presence of NF200 staining (indicative of intact neuronal processes). The size of the kill zone was then calculated in 10° bins around the 360° perimeter of the implant site by subtracting the location of the implant site from the location of NF200 staining. These 36 distance measures were used to calculate the mean kill zone size and compared via the rank sum test.

**[0162]** For quantification of Iba1 and GFAP staining, DAPI-stained images were again used to determine the perimeter of the implant site. Threshold values based on 95% of the background staining for each section were established. The amount of staining above this threshold value was then quantified and reported as a function of distance from the implant site. The median intensity values were binned every 50 μm from the implant site and compared via the rank sum test.

**[0163]** For NeuN/caspase-3 stained images, the number of NeuN/caspase-3 positive cells was quantified and reported as a percentage of the total number of NeuN positive cells.

**[0164]** Comparisons between any two groups of data were accomplished using the unpaired t test at the 95% confidence interval. A p value  $\leq 0.05$  was considered statistically significant.

## Results

**[0165]** In Vitro Studies. To determine if the L1 coating could increase neuronal density and decrease gliosis, the cellular attachment of neurons, astrocytes and microglia for different surface conditions were quantified and compared (FIG. 1). Parylene-C insulated probes were selected as the implant model because a number of widely used neural electrode arrays include parylene-C as an insulator. A two-step approach to immobilize proteins onto the parylene-C surface was used. Plasma treatment was first used to provide a charged polar group at the surface to facilitate protein binding. Protein was then adsorbed onto the activated surface. The effectiveness of protein immobilization was verified by testing the cellular response in culture. In comparison to the uncoated probes, a higher number of neurons were observed on the L1- and laminin-coated probes while there were fewer activated microglia (FIG. 1). L1 is a neuron-specific adhesion molecule that promotes growth and adhesion via hemophilic binding while laminin is an extracellular matrix protein that binds to multiple cells types via the integrin receptors. Therefore, the coating method was effective in immobilizing proteins and maintaining their respective biological functionality. In addition, the cellular responses associated with wires coated with the proteins and soaked in media for 5 days were similar to those observed with freshly-coated wires indicating good coating stability. As the L1-coated microwires demonstrated the desired properties for an improved neural tissue interface in vitro, this surface modification for subsequent in vivo work.

**[0166]** Characterization of the tissue response in the spinal cord.

**[0167]** A number of histological stains were performed to evaluate and characterize the tissue reaction in response to the NM and L1-coated probes (antibodies outlined in Table 3). First, to determine the degree of neuronal and axonal loss around the implant site, NF200 was used. In the spinal cord, NF200 staining is decreased or absent in the area immediately surrounding the implant site (FIG. 2). This area, termed the kill zone, was evident at both 1 week (FIG. 2A) and 4 week (FIG. 2B) time points. MATLAB was used to quantify kill

zone sizes which were then compared via the rank sum test. In the spinal cord and at both time points, the size of the kill zone was significantly reduced ( $p < 0.001$ ) with the L1 coating as compared to the NM microelectrodes (FIG. 3).

**[0168]** The non-neuronal cell response was also characterized, including the reactions associated with microglia/macrophages, astrocytes and fibroblasts using Iba1, GFAP and vimentin antibodies, respectively. Cells that stained positive for Iba1 were localized to the area immediately surrounding the implant. The staining intensity was greatest at the interface and decreased in intensity further from the implant (FIG. 4). MATLAB was again utilized to assess the decay in Iba1 staining. For this analysis, decay as a function of distance from the implant site was graphically represented and the median intensity values in 50 μm bins were compared via the rank sum test (as shown in FIG. 4). In the spinal cord, there was little difference between NM and L1-coated probes at the 1 week time point (FIG. 4A). However, at 4 weeks, the intensity of Iba1 staining was significantly higher with the NM probes (FIG. 4B).

**[0169]** GFAP-positive cells, identified as reactive astrocytes, resulted in the formation of a sheath a short distance from the electrode-tissue interface (FIG. 5). Vimentin-positive cells were localized at and around the implant site with some co-localization with GFAP. Cells that were vimentin positive and GFAP negative were identified as microglia, endothelial cells and fibroblasts. To quantify GFAP staining, the same MATLAB analyses used for Iba1 staining quantification were used. In the spinal cord, there was little difference in GFAP staining intensity between acute and chronic time points (FIG. 6) although there were significant differences between the NM and L1 electrodes between 50-150 μm at 1 week and 150-300 μm at 4 weeks.

**[0170]** Finally, to determine the impact on neuronal cell death, the colocalization of NeuN and activated caspase-3 was determined (representative images provided in FIG. 7). In the spinal cord, L1-coated probes were associated with a decrease in the percentage of neuronal cell death as assessed by the number of NeuN/caspase-3 positive cells versus NeuN positive cells at both acute and chronic time points (Table 4).

**[0171]** Characterization of the Tissue Response in the DRG.

**[0172]** The same histological stains used in the spinal cord were also used to assess the tissue response in the DRG. For NF200, staining intensity was decreased or absent in the area immediately surrounding the implant site (FIG. 8). Again, this kill zone was evident at both acute (FIG. 8A) and chronic (FIG. 8B) time points. In the DRG as in the spinal cord, the size of the kill zone was significantly reduced at both time points with the L1 coating as compared to the NM microelectrodes ( $p < 0.001$ ; FIG. 9).

**[0173]** For Iba1 staining, a significant decrease in staining intensity was observed at the 1 week time point in the DRG with the L1 coating (FIGS. 8A and 10A). Interestingly, the intensity of Iba1 staining was higher in the L1-modified group in the DRG at the 4 week time point when compared with the NM probes (FIGS. 8B and 10B).

**[0174]** In the DRG, there was a significant decrease in GFAP staining intensity at the 1 week time point with the L1 coating (FIGS. 11 and 12A). However, the intensity of GFAP staining was increased in the DRG at the 4 week time point at distances up to 150 μm from the interface with L1-coated microelectrodes (FIGS. 11 and 12B).

[0175] Finally, L1-coated probes in the DRG were associated with a decrease in the percentage of neuronal cell death at both time points analyzed (FIG. 13 and Table 4) as observed in the spinal cord.

TABLE 2

Animals in each treatment group			
Site of Implant	Time Point	Number of Animals (NM)	Number of Animals (L1)
DRG	1 week	n = 3	n = 3
DRG	4 weeks	n = 3	n = 3
spinal cord	1 week	n = 3	n = 3
spinal cord	4 weeks	n = 4	n = 3

TABLE 3

Antibodies used for histological characterization	
Antibody	Specificity
NF200	Mature axons
Iba1	Microglia/macrophages
GFAP	Astrocytes
Vimentin	Immature and reactive astrocytes, microglia, endothelial cells, fibroblasts
NeuN	Neuronal nuclei
Caspase-3	Cleaved (activated) caspase-3

TABLE 4

NeuN/Caspase-3 colocalization			
Location	Time Point (week)	Coating Condition	Percentage of NeuN/Caspase-3 Positive Cells
spinal cord	1	NM	11.3% (18 of 160)
		L1	5.1% (12 of 235)
	4	NM	21.8% (36 of 165)
		L1	7.0% (31 of 440)
DRG	1	NM	67.9% (142 of 209)
		L1	31.5% (23 of 73)
	4	NM	68.9% (51 of 74)
		L1	12.4% (31 of 249)

## DISCUSSION

[0176] One of the remaining challenges in the development of long-term neural interfaces or neuroprosthetics is maintenance of the cellular environment surrounding the implant. In particular, preventing neuronal cell death, promoting neuronal health and minimizing the inflammatory response are critical for success. Both central and peripheral nervous system sites including the spinal cord and DRG, respectively, are important target implant sites for such devices. In this study, the cellular response in these less well-studied locations was compared at both acute and chronic time points and the ability of L1 surface modifications to improve the tissue-electrode interface was investigated. The results indicate that neuronal density and health are significantly improved in the presence of the L1 surface modification in both central and peripheral locations.

[0177] The Cellular Response to Implanted Probes in the Spinal Cord and DRG.

[0178] As potential sites for interfacing with neural prosthetics, it is important to understand the tissue response to neural probes implanted in the spinal cord and DRG. In the spinal cord, a significant decrease in the amount of staining for neuronal processes was observed immediately surrounding implant sites for non-modified probes (FIG. 2). This kill zone was apparent at both the acute and chronic time points. However, the size of the kill zone was significantly larger at the 1 week time point (median size of 174.56  $\mu\text{m}$ ) than at the 4 week time point (median size of 145.56  $\mu\text{m}$ ;  $p < 0.001$ ) suggesting some degree of axonal regeneration following injury.

[0179] In the central nervous system, microglia are resident cells that are activated along with astrocytes in response to injury. In both central and peripheral tissues, invading cells express Iba1, a calcium binding protein localized exclusively to microglial cells in the nervous system (Ito et al., *Brain Res Mol Brain Res*, 57:1-9, 1998; Patro et al., *Indian J Exp Biol*, 48:110-6, 2010). This protein plays an important role in cell migration and mediates the phagocytic activity of microglia (Ohsawa et al., *J Biomed Mater Res*, 52:460-6, 2000). Iba1 is also up-regulated in a variety of conditions indicating its importance in the activated microglial phenotype (Ito et al., *Brain Res Mol Brain Res*, 57:1-9, 1998; Ohsawa et al., *J Biomed Mater Res*, 52:460-6, 2000; Ito et al., *Stroke*, 32:1208-15, 2001; Mori et al., *Brain Res Mol Brain Res*, 120:52-6, 2003). For the Iba1-mediated component of the inflammatory response, increased staining was observed in the area immediately surrounding the implant with levels reaching that of the background as the distance from the interface increased. Although both acute and chronic time points experienced this decay as a function of distance, the overall intensity of the Iba1 response was significantly greater at the 1 week time point at distances ranging from 0-250  $\mu\text{m}$  (0-50  $\mu\text{m}$ ,  $p < 0.01$ ; 50-100  $\mu\text{m}$ ,  $p < 0.01$ ; 100-150  $\mu\text{m}$ ,  $p < 0.05$ ; 150-200  $\mu\text{m}$ ,  $p < 0.001$ ; 200-250  $\mu\text{m}$ ,  $p < 0.05$ ). Astrocyte staining patterns for the uncoated probes were characterized by a sheath a short distance from the interface. Again, the formation of this glial scar was observed at both time points with a decline in staining intensity to background levels as the distance from the interface increased. However, there was a significant increase in the intensity of GFAP staining between 50 and 100  $\mu\text{m}$  at the 4 week point ( $p < 0.01$ ) suggesting that the uncoated probes continued to promote astrocyte migration after the acute injury. Vimentin staining was also assessed as this protein is expressed by a number of cell types including immature and reactive astrocytes, microglia, endothelial cells and fibroblasts.

[0180] The response observed in the DRG was similar in many ways to that observed in the spinal cord. For example, a decrease in the amount of neuronal process staining in the kill zone was observed in this peripheral site and at both time points studied (FIG. 8). The size of the kill zone was significantly larger at the 1 week time point (median size of 190.18  $\mu\text{m}$ ) than at the 4 week time point (median size of 148.65  $\mu\text{m}$ ;  $p < 0.001$ ) again suggesting a regenerative process following injury.

[0181] In peripheral tissues like the DRG, it is believed that immune cells also invade following injury (Bennett et al., *J Neurosci*, 18:3059-72, 1998; Hu et al., *Brain Behav Immun*, 21:599-616, 2007) and some of these cells express Iba1. The Iba1-mediated component of the inflammatory response in

the DRG resembled that of the spinal cord. Iba1 staining in the area immediately surrounding the implant was increased and levels reached that of the background with increasing distance from the interface. In comparing the 1 and 4 week time points, the overall intensity of the Iba1 response was significantly greater at the 1 week time point at distances up to 350  $\mu\text{m}$  from the interface (0-50  $\mu\text{m}$ ,  $p < 0.001$ ; 50-100  $\mu\text{m}$ ,  $p < 0.001$ ; 100-150  $\mu\text{m}$ ,  $p < 0.001$ ; 150-200  $\mu\text{m}$ ,  $p < 0.001$ ; 200-250  $\mu\text{m}$ ,  $p < 0.01$ ; 250-300  $\mu\text{m}$ ,  $p < 0.05$ ; 300-350  $\mu\text{m}$ ,  $p < 0.05$ ). The GFAP staining observed in the DRG can be attributed to satellite glial cells (SGCs) which ensheath the DRG perikarya after injury (Hanani et al., *Brain Res Brain Res Rev*, 48:457-76, 2005) and are thought to control the neuronal microenvironment in the DRG (Keast and Stephensen, *J Comp Neurol*, 424:577-87, 2000). Finally, caspase-3-mediated neuronal apoptosis was also observed in the DRG as in the spinal cord.

**[0182]** Effects of the L1 Coating.

**[0183]** In terms of neuronal presence around the implants, significant decreases were observed in the size of the kill zone with the L1 coating at both 1 week and 4 weeks and in the spinal cord (FIG. 3) and DRG (FIG. 9). In addition, neuronal health appeared to improve in the presence of L1 as a significantly lower percentage of neurons were positive for activated caspase-3, an important cellular mediator of programmed cell death (FIGS. 7 and 13 and Table 4). This may be due to the regenerative responses associated with L1 following nervous system injury. Taken together, these results indicate that the L1 immobilized on the implanted microelectrodes can promote regeneration of injured neurons or axons near the implant site.

**[0184]** In the spinal cord, our analyses indicate that Iba1 staining intensity only differed between NM and L1-coated microelectrodes at distances 50-100  $\mu\text{m}$  from the implant site at the early time point although at the 4 week time point there was a significant decrease in Iba1 staining intensity with the L1 coating at distances 50-300  $\mu\text{m}$  from the implant site. In the DRG, a decrease in Iba1 staining intensity was observed with L1 at the 1 week time point and then an increase in Iba1 intensity with L1 at the 4 week time point.

**[0185]** Reactive astrogliosis is a prominent response of the central nervous system to injury and can be characterized by increased expression of GFAP, cell and process enlargement and proliferation (Sofroniew and Vinters, *Acta Neuropathol*, 119:7-35, 2010). This leads to local accumulation of astrocytes and formation of what is termed the glial scar, characterized by the deposition of a dense extracellular matrix (Irintchev and Schachner, *Neuroscientist*, 18:452-466, 2011). Although a significant difference in GFAP staining intensity was not observed in the spinal cord with the L1 staining, GFAP immunoreactivity for both NM and L1-modified probes increased as a function of time. As reported by other groups, reactive astrocytes progressively displace neurons away from the recording zone, a mechanism that likely accounts for failure during single unit recordings in the brain (Polikov et al., *J Neurosci Methods*, 148:1-18, 2005; Szarowski et al., *Brain Res*, 983:23-35, 2003).

**[0186]** In summary, immobilization of L1 protein significantly promotes neuronal density and neuronal health at the tissue-probe interface at both acute and chronic time points. These results suggest that immobilization of L1 may increase the biocompatibility of neural probes used both centrally and peripherally for rehabilitative and therapeutic purposes.

## Example 2

### Coating Neural Probes with Brain Derived Neural Adhesion Molecule L1

**[0187]** This example illustrated surface immobilization protocols to coat neuron specific cell adhesion molecule L1 on various neural probes with different surface chemistry.

**[0188]** The cell adhesion molecule L1 was purified by immunoaffinity chromatography as previously described (Lagenaur and Lemmon, *Proc. Natl. Acad. Sci. USA*, 1987, 84: p. 7753-7757).

**[0189]** For neural probes with silicon oxide surface, silane chemistry and a GMBS crosslinker are used to covalently attach L1 and polyethylene glycol on surfaces. Characterization of the surface using dual polarization interferometry indicates that the surface bound L1 mass is 2.67  $\text{ng}/\text{mm}^2$  (Azemi et al., *Acta Biomaterialia*, 2008, 4(5): p. 1208-1217; incorporated by reference herein in its entirety). NeuroNexus probes were coated using this approach and implanted for 1, 4 and 8 weeks. The effects of L1 were evaluated with immunohistochemistry and quantitative image analysis. Whereas non-modified probes induced persistent glial activation and significant decreases of neuronal and axonal densities (FIG. 14), the immediate area (100  $\mu\text{m}$ ) around the L1 coated probe showed no loss of neuronal bodies and a significantly increased axonal density relative to background (FIGS. 14A-14D). In this same region, significantly lower activation of microglia and reaction of astrocytes around the L1 modified probes were found when compared to the control probes (FIGS. 14E-14G) (Azemi et al., *Biomaterials*, 2011, 32(3): p. 681-92).

**[0190]** Several coating strategies were developed to immobilize proteins on a parylene C surface. The first approach utilized air plasma to modify the parylene C surface with polar hydroxyl groups at the surface, as previously described (see Chang et al., *Langmuir*, 2007, 23(23): p. 11718-25; Sia and Whitesides, *Electrophoresis*, 2003, 24(21): p. 3563-76, which is incorporated by reference herein in its entirety). The probes are then soaked in L1 containing protein solution for 1 hour. The successful attachment of the L1 protein was characterized by immunostaining and the bioactivity of the L1 coated probe was verified in cell culture (Kolarcik et al., *Acta Biomater*, 2012, 8(10): p. 3561-75).

**[0191]** Two additional coating methods have also been developed that can covalently attach proteins on parylene C surfaces. The first method involves surface treatment of parylene C with succinic anhydride to add carboxylic acid groups on the surface, which can then react with amine on proteins (FIG. 15E) (succinic anhydride treatment of parylene C has been previously described, see, e.g., Zhang et al., *Acta Biomater*, 2011, 7(10): p. 3746-56, which is incorporated by reference herein in its entirety).

**[0192]** An additional method involves the synthesis of diamino(2,2)paracyclophane by nitration of (2,2)paracyclophane and subsequent reduction of the nitro groups. The diamino(2,2)paracyclophane can then form a parylene coating in a CVD chamber which has amine groups available for protein binding (FIG. 15F) (see, e.g., Lahann et al., *Angew Chem Int Ed Engl*, 2001, 40(16): p. 2947, which is incorporated by reference herein in its entirety).

**[0193]** To promote neuronal attachment on the tip of the recording electrode, two methods are found to be effective: 1) Direct co-deposition of conducting polymer and L1 on electrode sites (FIGS. 16A-16B); and 2) Polyethylenedioxi-

ythiophene (PEDOT) doped with graphene oxide (GO) which can then be covalently linked to protein via carboxylic acid groups on GO (FIGS. 16C-16D) (Luo et al., *J Mat. Chem. B*, 2013, 1(1): p. 1340-1348, which is incorporated by reference herein in its entirety).

### Example 3

#### L1 Coating Improves Chronic Recording Performance

**[0194]** L1 was isolated from rhesus monkey brain (World-wide Primate) using known methods (see, e.g., Lagenaur and Lemmon, *Proc. Natl. Acad. Sci. USA*, 1987, 84: p. 7753-7757, incorporated by reference herein in its entirety). An L1 coated 96 channel Blackrock array (coated using protein adsorption of L1 as described herein), and a non-coated array were implanted in the right hemisphere motor cortex of a monkey. The L1 coated arrays detected 120 single-units on day 2 and the unit counts continued to increase to 240 on day 75 (FIG. 17). Remarkably, many channels have more than one and up to 7 well isolated single-units (FIG. 17b). The amplitude of some of the units can be as high as 1 mV (FIG. 17D). The increases continued for extended time periods, with excellent recording performance maintained at 18 months post-implant (FIG. 18A). On some channels, unit waveforms are very stable and signal amplitudes are extraordinarily large even at day 447 (FIG. 18B). This high amplitude suggest that the neuron is directly on the electrode site with very tight cell-electrode seal (Pettersen and Einevoll, *Biophys J*, 2008, 94(3): p. 784-802.).

### Example 4

#### Production of L1 Coated Probes

**[0195]** This example illustrates exemplary methods of producing and sterilizing L1 coated probes.

**[0196]** Several approaches have been developed to covalently attach the L1 polypeptide to the surface of silicon dioxide or parylene C coated neural probes, and store the probes for future use. However, immobilized protein tends to denature easily in nonphysiological conditions. For example, ethylene oxide sterilization treatment completely destroys the bioactivity of L1 attached to parylene C coverslips as demonstrated by the poor neuronal attachment and neurite growth in culture (FIG. 20B). Drying in air reduces protein activity, though bioactivity is still retained (FIG. 20C). Methods of producing L1 coated probes are described below, concerning coating for both parylene C-insulated and silicon dioxide-insulated probes.

**[0197]** In a first approach, to produce a L1-coated probe that that can be directly sterilized, an L1 protein-polymer conjugate can be synthesized and then conjugated to a modified neural probe. Polymer-protein conjugates have been synthesized which maintain, and in some cases enhance, performance of the conjugated protein, while improving stability during storage as well as sterilization (Thilakarathne et al., 2011, 27(12): p. 7663-7671). L1 can be covalently attached to the carboxyl functional groups of poly(acrylic acid) (PAA) and lightly cross-linked (e.g., with EDC chemistry), resulting in a stable and soluble L1-polymer conjugate. For silicon oxide substrates, the L1-polymer conjugate can then be covalently attached to the silicon oxide surface using traditional silanization/GMBS methods as described above. For parylene C substrates, two exemplary immobilization strate-

gies can be utilized: a) direct attachment to the parylene C surface following oxygen plasma treatment; or b) attachment to the parylene C surface via EDC/NHS cross-linking following oxygen plasma treatment. For these protocols, Clean parylene C substrates are exposed to O<sub>2</sub> plasma for 15 s (30 W). Immediately afterwards, the substrates are submerged in a sterile H<sub>2</sub>O solution containing 0.2M EDC and 0.2M NHS and incubated at room temperature for 1 hr. After rinsing the substrates, the EDC/NHS functionalized surfaces are incubated in the L1-protein solution (100 μg/mL) for 1 hr. Protein coated parylene C substrates are then rinsed repeatedly prior to subsequent experiments.

**[0198]** FIGS. 21-22 illustrate conjugation of L1 to a parylene C surface via EDC/NHS cross-linking following oxygen plasma treatment. A parylene C coated coverslip was treated with oxygen plasma as described (see, e.g., Golda et al., 2013, *Materials Science and Engineering*, 33: 4221-4227, incorporated by reference in its entirety). The treated coverslip was then incubated with succinimide overnight, and EDC/NHS chemistry was used to crosslink the L1 to the parylene C coated coverslip substrate (FIG. 21A). The coupling reaction was monitored as shown in FIGS. 21B and 21C. To monitor coupling, the bioactivity of the coated samples was assessed by determining the bioactivity of the samples, neurons are plated onto the surface and grown for 3 days. On day 3, cells are fixed and examined for cell density and neurite outgrowth. The increase in N 1 s at ~400 indicates successful attachment of succinimidyl ester. Protein functionalization verified by increases in N is and the increase in O/N:Cl ratio. After coupling L1 to the parylene coat on the coverslip using EDC/NHS chemistry following oxygen plasma treatment, neuron growth is promoted and neurite outgrowth is extensive (FIG. 22). However, neuron growth was not observed if the L1 coat was performing the EDC/NHS chemistry without prior oxygen plasma treatment.

**[0199]** In another approach, for production of a sterile coating that is preserved under restricted conditions prior to use, three exemplary protocols are provided:

**[0200]** 1: Substrates can be coated with L1 using previously discussed techniques for silicon oxide and parylene C and immediately freeze-dried. Freeze-drying has been used to prolong the activity of proteins in storage at low temperatures for both free and immobilized proteins (see, e.g., Neil et al., *Biomacromolecules*, 2009, 10(9): p. 2577-2583, which is incorporated by reference herein). Coated samples can be maintained at -20° C. in the presence of desiccant for 1 week (or longer) at which point the samples can be rehydrated with sterile PBS prior to use.

**[0201]** 2: Prior to freeze-drying the protein-coated substrates (as in 1 above), each prepared substrate can be lightly cross-linked via free radical oxidation. Low levels of superoxide improved the stability of air-dried, L1-coated substrates (see FIG. 20D), which may be a result of the known cross-linking capabilities of oxidative species and the increased stability of more rigid cross-linked proteins (see, e.g., Brisson et al., *Function of Oxidative Cross-Linking of Cell Wall Structural Proteins in Plant Disease Resistance*. The Plant Cell Online, 1994, 6(12): p. 1703-1712; Choquet et al., *Cell*, 1997, 88(1): p. 39-48).

**[0202]** 3: A protective coating composed of layer-by-layer-deposited mannitol and polyelectrolytes can be used to seal the prepared L1-coated substrates and to improve stability prior to freeze-drying (as in 1 above). This approach has been previously described in the context of protecting vaccine

antigen (see, e.g., Dierendonck et al., ACS Nano, 2011, 5(9): p. 6886-93, which is incorporated by reference herein). Stored L1 coated probes can then be rehydrated with sterile PBS to dissolve the protective coating. Alternatively, polyethylene glycol gel may be applied to preserve the bioactivity of the underlying protein upon freeze-drying and storage, a method that has shown effective in preserving and even increasing the bioactivity of glucose oxidase in glucose sensors.

**[0203]** In an additional approach, for a multi-component shipping strategy, the neural probe (prior to L1 coating) can be prepared using previously described techniques for silicon oxide or parylene C substrates; however, prior to the L1-immobilization step, the “activated” substrates can be 1) air dried; 2) freeze-dried; or 3) inert-gas dried (N<sub>2</sub>/Ar). The substrates can then be packaged and sent to a user along with an appropriate amount of purified L1 to conjugate to the substrate to generate the L1 coated probe for use. For example, following shipping, the substrates can be submerged in a sterile L1 solution and tested for bioactivity.

**[0204]** Multiple tests can be used to assay the L1-coated probe. For example, the bioactivity of the coating can be determined using neuronal and glial cell cultures. Primary neurons grown on an L1-coated surface have a characteristic growth pattern of very long and straight processes. Therefore, neurite length can be quantified as a metric to determine bioactivity of the L1. Astrocyte attachment, on the other hand, is inhibited by L1, so the amount of astrocyte attachment, which inversely relates to the activity of L1, can also be used as another quantifiable metric. Additionally, the neural recording capability can be assessed by applying the L1 coating to commercially available probes (e.g., Blackrock or NeuroNexus arrays) which are implanted into neural tissue in an animal model (e.g., rat neural cortex). A visually evoked

recording model will be used to assess recording quality, stability and longevity against an uncoated control on the contralateral side.

#### Example 5

##### Recombinant Human L1 Promotes Neurite Outgrowth

**[0205]** This example illustrates that recombinant L1 promotes neurite outgrowth. Recombinant human L1 was purchased from Millipore (CAT: GF220) and conjugated to parylene-C coated coverslips using the oxygen plasma initiated EDC/NHS coupling method described above. As shown in FIG. 23, L1 isolated fresh from rat pup cortical tissue (FIG. 23A) as well as the recombinant human L1 (expressed in HEK293 cells)(FIG. 23B) both promoted neurite outgrowth using the method.

#### Example 6

##### Cross-Reactivity of L1 Orthologues

**[0206]** This example illustrates that L1 orthologues can support growth of neurons from multiple species. L1 freshly isolated from monkey brain was covalently linked to parylene-C coated coverslips and primary cortical neuron cultures from rat brain were seeded on to the coverslips. The rat neurons successfully attached to the coverslips and produced extensive neurite outgrowth, indicating that the monkey L1 successfully supports growth of rat neurons (FIG. 24).

**[0207]** It will be apparent that the precise details of the methods or compositions described may be varied or modified without departing from the spirit of the described embodiments. We claim all such modifications and variations that fall within the scope and spirit of the claims below.

---

#### SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 4

<210> SEQ ID NO 1
<211> LENGTH: 1257
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 1

Met Val Val Ala Leu Arg Tyr Val Trp Pro Leu Leu Leu Cys Ser Pro
1          5          10
Cys Leu Leu Ile Gln Ile Pro Glu Glu Tyr Glu Gly His His Val Met
20         25
Glu Pro Pro Val Ile Thr Glu Gln Ser Pro Arg Arg Leu Val Val Phe
35         40         45
Pro Thr Asp Asp Ile Ser Leu Lys Cys Glu Ala Ser Gly Lys Pro Glu
50         55         60
Val Gln Phe Arg Trp Thr Arg Asp Gly Val His Phe Lys Pro Lys Glu
65         70         75         80
Glu Leu Gly Val Thr Val Tyr Gln Ser Pro His Ser Gly Ser Phe Thr
85         90         95
Ile Thr Gly Asn Asn Ser Asn Phe Ala Gln Arg Phe Gln Gly Ile Tyr
100        105        110
Arg Cys Phe Ala Ser Asn Lys Leu Gly Thr Ala Met Ser His Glu Ile

```



-continued

115			120			125									
Arg	Leu	Met	Ala	Glu	Gly	Ala	Pro	Lys	Trp	Pro	Lys	Glu	Thr	Val	Lys
130					135						140				
Pro	Val	Glu	Val	Glu	Gly	Glu	Ser	Val	Val	Leu	Pro	Cys	Asn	Pro	
145				150					155					160	
Pro	Pro	Ser	Ala	Glu	Pro	Leu	Arg	Ile	Tyr	Trp	Met	Asn	Ser	Lys	Ile
			165						170					175	
Leu	His	Ile	Lys	Gln	Asp	Glu	Arg	Val	Thr	Met	Gly	Gln	Asn	Gly	Asn
			180					185						190	
Leu	Tyr	Phe	Ala	Asn	Val	Leu	Thr	Ser	Asp	Asn	His	Ser	Asp	Tyr	Ile
		195					200					205			
Cys	His	Ala	His	Phe	Pro	Gly	Thr	Arg	Thr	Ile	Ile	Gln	Lys	Glu	Pro
210						215					220				
Ile	Asp	Leu	Arg	Val	Lys	Ala	Thr	Asn	Ser	Met	Ile	Asp	Arg	Lys	Pro
225					230					235					240
Arg	Leu	Leu	Phe	Pro	Thr	Asn	Ser	Ser	Ser	His	Leu	Val	Ala	Leu	Gln
			245						250					255	
Gly	Gln	Pro	Leu	Val	Leu	Glu	Cys	Ile	Ala	Glu	Gly	Phe	Pro	Thr	Pro
			260					265						270	
Thr	Ile	Lys	Trp	Leu	Arg	Pro	Ser	Gly	Pro	Met	Pro	Ala	Asp	Arg	Val
		275					280					285			
Thr	Tyr	Gln	Asn	His	Asn	Lys	Thr	Leu	Gln	Leu	Leu	Lys	Val	Gly	Glu
		290				295					300				
Glu	Asp	Asp	Gly	Glu	Tyr	Arg	Cys	Leu	Ala	Glu	Asn	Ser	Leu	Gly	Ser
305					310					315					320
Ala	Arg	His	Ala	Tyr	Tyr	Val	Thr	Val	Glu	Ala	Ala	Pro	Tyr	Trp	Leu
			325						330					335	
His	Lys	Pro	Gln	Ser	His	Leu	Tyr	Gly	Pro	Gly	Glu	Thr	Ala	Arg	Leu
			340					345						350	
Asp	Cys	Gln	Val	Gln	Gly	Arg	Pro	Gln	Pro	Glu	Val	Thr	Trp	Arg	Ile
		355					360					365			
Asn	Gly	Ile	Pro	Val	Glu	Glu	Leu	Ala	Lys	Asp	Gln	Lys	Tyr	Arg	Ile
		370				375					380				
Gln	Arg	Gly	Ala	Leu	Ile	Leu	Ser	Asn	Val	Gln	Pro	Ser	Asp	Thr	Met
385					390					395					400
Val	Thr	Gln	Cys	Glu	Ala	Arg	Asn	Arg	His	Gly	Leu	Leu	Leu	Ala	Asn
			405						410					415	
Ala	Tyr	Ile	Tyr	Val	Val	Gln	Leu	Pro	Ala	Lys	Ile	Leu	Thr	Ala	Asp
			420					425						430	
Asn	Gln	Thr	Tyr	Met	Ala	Val	Gln	Gly	Ser	Thr	Ala	Tyr	Leu	Leu	Cys
		435					440					445			
Lys	Ala	Phe	Gly	Ala	Pro	Val	Pro	Ser	Val	Gln	Trp	Leu	Asp	Glu	Asp
		450				455					460				
Gly	Thr	Thr	Val	Leu	Gln	Asp	Glu	Arg	Phe	Phe	Pro	Tyr	Ala	Asn	Gly
465					470					475					480
Thr	Leu	Gly	Ile	Arg	Asp	Leu	Gln	Ala	Asn	Asp	Thr	Gly	Arg	Tyr	Phe
			485						490					495	
Cys	Leu	Ala	Ala	Asn	Asp	Gln	Asn	Asn	Val	Thr	Ile	Met	Ala	Asn	Leu
			500					505						510	
Lys	Val	Lys	Asp	Ala	Thr	Gln	Ile	Thr	Gln	Gly	Pro	Arg	Ser	Thr	Ile
		515						520						525	

-continued

---

Glu Lys Lys Gly Ser Arg Val Thr Phe Thr Cys Gln Ala Ser Phe Asp  
 530 535 540

Pro Ser Leu Gln Pro Ser Ile Thr Trp Arg Gly Asp Gly Arg Asp Leu  
 545 550 555 560

Gln Glu Leu Gly Asp Ser Asp Lys Tyr Phe Ile Glu Asp Gly Arg Leu  
 565 570 575

Val Ile His Ser Leu Asp Tyr Ser Asp Gln Gly Asn Tyr Ser Cys Val  
 580 585 590

Ala Ser Thr Glu Leu Asp Val Val Glu Ser Arg Ala Gln Leu Leu Val  
 595 600 605

Val Gly Ser Pro Gly Pro Val Pro Arg Leu Val Leu Ser Asp Leu His  
 610 615 620

Leu Leu Thr Gln Ser Gln Val Arg Val Ser Trp Ser Pro Ala Glu Asp  
 625 630 635 640

His Asn Ala Pro Ile Glu Lys Tyr Asp Ile Glu Phe Glu Asp Lys Glu  
 645 650 655

Met Ala Pro Glu Lys Trp Tyr Ser Leu Gly Lys Val Pro Gly Asn Gln  
 660 665 670

Thr Ser Thr Thr Leu Lys Leu Ser Pro Tyr Val His Tyr Thr Phe Arg  
 675 680 685

Val Thr Ala Ile Asn Lys Tyr Gly Pro Gly Glu Pro Ser Pro Val Ser  
 690 695 700

Glu Thr Val Val Thr Pro Glu Ala Ala Pro Glu Lys Asn Pro Val Asp  
 705 710 715 720

Val Lys Gly Glu Gly Asn Glu Thr Thr Asn Met Val Ile Thr Trp Lys  
 725 730 735

Pro Leu Arg Trp Met Asp Trp Asn Ala Pro Gln Val Gln Tyr Arg Val  
 740 745 750

Gln Trp Arg Pro Gln Gly Thr Arg Gly Pro Trp Gln Glu Gln Ile Val  
 755 760 765

Ser Asp Pro Phe Leu Val Val Ser Asn Thr Ser Thr Phe Val Pro Tyr  
 770 775 780

Glu Ile Lys Val Gln Ala Val Asn Ser Gln Gly Lys Gly Pro Glu Pro  
 785 790 795 800

Gln Val Thr Ile Gly Tyr Ser Gly Glu Asp Tyr Pro Gln Ala Ile Pro  
 805 810 815

Glu Leu Glu Gly Ile Glu Ile Leu Asn Ser Ser Ala Val Leu Val Lys  
 820 825 830

Trp Arg Pro Val Asp Leu Ala Gln Val Lys Gly His Leu Arg Gly Tyr  
 835 840 845

Asn Val Thr Tyr Trp Arg Glu Gly Ser Gln Arg Lys His Ser Lys Arg  
 850 855 860

His Ile His Lys Asp His Val Val Val Pro Ala Asn Thr Thr Ser Val  
 865 870 875 880

Ile Leu Ser Gly Leu Arg Pro Tyr Ser Ser Tyr His Leu Glu Val Gln  
 885 890 895

Ala Phe Asn Gly Arg Gly Ser Gly Pro Ala Ser Glu Phe Thr Phe Ser  
 900 905 910

Thr Pro Glu Gly Val Pro Gly His Pro Glu Ala Leu His Leu Glu Cys  
 915 920 925

-continued

---

Gln Ser Asn Thr Ser Leu Leu Leu Arg Trp Gln Pro Pro Leu Ser His  
 930 935 940  
 Asn Gly Val Leu Thr Gly Tyr Val Leu Ser Tyr His Pro Leu Asp Glu  
 945 950 955 960  
 Gly Gly Lys Gly Gln Leu Ser Phe Asn Leu Arg Asp Pro Glu Leu Arg  
 965 970 975  
 Thr His Asn Leu Thr Asp Leu Ser Pro His Leu Arg Tyr Arg Phe Gln  
 980 985 990  
 Leu Gln Ala Thr Thr Lys Glu Gly Pro Gly Glu Ala Ile Val Arg Glu  
 995 1000 1005  
 Gly Gly Thr Met Ala Leu Ser Gly Ile Ser Asp Phe Gly Asn Ile  
 1010 1015 1020  
 Ser Ala Thr Ala Gly Glu Asn Tyr Ser Val Val Ser Trp Val Pro  
 1025 1030 1035  
 Lys Glu Gly Gln Cys Asn Phe Arg Phe His Ile Leu Phe Lys Ala  
 1040 1045 1050  
 Leu Gly Glu Glu Lys Gly Gly Ala Ser Leu Ser Pro Gln Tyr Val  
 1055 1060 1065  
 Ser Tyr Asn Gln Ser Ser Tyr Thr Gln Trp Asp Leu Gln Pro Asp  
 1070 1075 1080  
 Thr Asp Tyr Glu Ile His Leu Phe Lys Glu Arg Met Phe Arg His  
 1085 1090 1095  
 Gln Met Ala Val Lys Thr Asn Gly Thr Gly Arg Val Arg Leu Pro  
 1100 1105 1110  
 Pro Ala Gly Phe Ala Thr Glu Gly Trp Phe Ile Gly Phe Val Ser  
 1115 1120 1125  
 Ala Ile Ile Leu Leu Leu Leu Val Leu Leu Ile Leu Cys Phe Ile  
 1130 1135 1140  
 Lys Arg Ser Lys Gly Gly Lys Tyr Ser Val Lys Asp Lys Glu Asp  
 1145 1150 1155  
 Thr Gln Val Asp Ser Glu Ala Arg Pro Met Lys Asp Glu Thr Phe  
 1160 1165 1170  
 Gly Glu Tyr Arg Ser Leu Glu Ser Asp Asn Glu Glu Lys Ala Phe  
 1175 1180 1185  
 Gly Ser Ser Gln Pro Ser Leu Asn Gly Asp Ile Lys Pro Leu Gly  
 1190 1195 1200  
 Ser Asp Asp Ser Leu Ala Asp Tyr Gly Gly Ser Val Asp Val Gln  
 1205 1210 1215  
 Phe Asn Glu Asp Gly Ser Phe Ile Gly Gln Tyr Ser Gly Lys Lys  
 1220 1225 1230  
 Glu Lys Glu Ala Ala Gly Gly Asn Asp Ser Ser Gly Ala Thr Ser  
 1235 1240 1245  
 Pro Ile Asn Pro Ala Val Ala Leu Glu  
 1250 1255

&lt;210&gt; SEQ ID NO 2

&lt;211&gt; LENGTH: 858

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: homo sapiens

&lt;400&gt; SEQUENCE: 2

Met Leu Gln Thr Lys Asp Leu Ile Trp Thr Leu Phe Phe Leu Gly Thr  
 1 5 10 15

-continued

---

Ala Val Ser Leu Gln Val Asp Ile Val Pro Ser Gln Gly Glu Ile Ser  
20 25 30

Val Gly Glu Ser Lys Phe Phe Leu Cys Gln Val Ala Gly Asp Ala Lys  
35 40 45

Asp Lys Asp Ile Ser Trp Phe Ser Pro Asn Gly Glu Lys Leu Thr Pro  
50 55 60

Asn Gln Gln Arg Ile Ser Val Val Trp Asn Asp Asp Ser Ser Ser Thr  
65 70 75 80

Leu Thr Ile Tyr Asn Ala Asn Ile Asp Asp Ala Gly Ile Tyr Lys Cys  
85 90 95

Val Val Thr Gly Glu Asp Gly Ser Glu Ser Glu Ala Thr Val Asn Val  
100 105 110

Lys Ile Phe Gln Lys Leu Met Phe Lys Asn Ala Pro Thr Pro Gln Glu  
115 120 125

Phe Arg Glu Gly Glu Asp Ala Val Ile Val Cys Asp Val Val Ser Ser  
130 135 140

Leu Pro Pro Thr Ile Ile Trp Lys His Lys Gly Arg Asp Val Ile Leu  
145 150 155 160

Lys Lys Asp Val Arg Phe Ile Val Leu Ser Asn Asn Tyr Leu Gln Ile  
165 170 175

Arg Gly Ile Lys Lys Thr Asp Glu Gly Thr Tyr Arg Cys Glu Gly Arg  
180 185 190

Ile Leu Ala Arg Gly Glu Ile Asn Phe Lys Asp Ile Gln Val Ile Val  
195 200 205

Asn Val Pro Pro Thr Ile Gln Ala Arg Gln Asn Ile Val Asn Ala Thr  
210 215 220

Ala Asn Leu Gly Gln Ser Val Thr Leu Val Cys Asp Ala Glu Gly Phe  
225 230 235 240

Pro Glu Pro Thr Met Ser Trp Thr Lys Asp Gly Glu Gln Ile Glu Gln  
245 250 255

Glu Glu Asp Asp Glu Lys Tyr Ile Phe Ser Asp Asp Ser Ser Gln Leu  
260 265 270

Thr Ile Lys Lys Val Asp Lys Asn Asp Glu Ala Glu Tyr Ile Cys Ile  
275 280 285

Ala Glu Asn Lys Ala Gly Glu Gln Asp Ala Thr Ile His Leu Lys Val  
290 295 300

Phe Ala Lys Pro Lys Ile Thr Tyr Val Glu Asn Gln Thr Ala Met Glu  
305 310 315 320

Leu Glu Glu Gln Val Thr Leu Thr Cys Glu Ala Ser Gly Asp Pro Ile  
325 330 335

Pro Ser Ile Thr Trp Arg Thr Ser Thr Arg Asn Ile Ser Ser Glu Glu  
340 345 350

Lys Ala Ser Trp Thr Arg Pro Glu Lys Gln Glu Thr Leu Asp Gly His  
355 360 365

Met Val Val Arg Ser His Ala Arg Val Ser Ser Leu Thr Leu Lys Ser  
370 375 380

Ile Gln Tyr Thr Asp Ala Gly Glu Tyr Ile Cys Thr Ala Ser Asn Thr  
385 390 395 400

Ile Gly Gln Asp Ser Gln Ser Met Tyr Leu Glu Val Gln Tyr Ala Pro  
405 410 415

-continued

---

Lys Leu Gln Gly Pro Val Ala Val Tyr Thr Trp Glu Gly Asn Gln Val  
 420 425 430  
 Asn Ile Thr Cys Glu Val Phe Ala Tyr Pro Ser Ala Thr Ile Ser Trp  
 435 440 445  
 Phe Arg Asp Gly Gln Leu Leu Pro Ser Ser Asn Tyr Ser Asn Ile Lys  
 450 455 460  
 Ile Tyr Asn Thr Pro Ser Ala Ser Tyr Leu Glu Val Thr Pro Asp Ser  
 465 470 475 480  
 Glu Asn Asp Phe Gly Asn Tyr Asn Cys Thr Ala Val Asn Arg Ile Gly  
 485 490 495  
 Gln Glu Ser Leu Glu Phe Ile Leu Val Gln Ala Asp Thr Pro Ser Ser  
 500 505 510  
 Pro Ser Ile Asp Gln Val Glu Pro Tyr Ser Ser Thr Ala Gln Val Gln  
 515 520 525  
 Phe Asp Glu Pro Glu Ala Thr Gly Gly Val Pro Ile Leu Lys Tyr Lys  
 530 535 540  
 Ala Glu Trp Arg Ala Val Gly Glu Glu Val Trp His Ser Lys Trp Tyr  
 545 550 555 560  
 Asp Ala Lys Glu Ala Ser Met Glu Gly Ile Val Thr Ile Val Gly Leu  
 565 570 575  
 Lys Pro Glu Thr Thr Tyr Ala Val Arg Leu Ala Ala Leu Asn Gly Lys  
 580 585 590  
 Gly Leu Gly Glu Ile Ser Ala Ala Ser Glu Phe Lys Thr Gln Pro Val  
 595 600 605  
 Gln Gly Glu Pro Ser Ala Pro Lys Leu Glu Gly Gln Met Gly Glu Asp  
 610 615 620  
 Gly Asn Ser Ile Lys Val Asn Leu Ile Lys Gln Asp Asp Gly Gly Ser  
 625 630 635 640  
 Pro Ile Arg His Tyr Leu Val Arg Tyr Arg Ala Leu Ser Ser Glu Trp  
 645 650 655  
 Lys Pro Glu Ile Arg Leu Pro Ser Gly Ser Asp His Val Met Leu Lys  
 660 665 670  
 Ser Leu Asp Trp Asn Ala Glu Tyr Glu Val Tyr Val Val Ala Glu Asn  
 675 680 685  
 Gln Gln Gly Lys Ser Lys Ala Ala His Phe Val Phe Arg Thr Ser Ala  
 690 695 700  
 Gln Pro Thr Ala Ile Pro Ala Asn Gly Ser Pro Thr Ser Gly Leu Ser  
 705 710 715 720  
 Thr Gly Ala Ile Val Gly Ile Leu Ile Val Ile Phe Val Leu Leu Leu  
 725 730 735  
 Val Val Val Asp Ile Thr Cys Tyr Phe Leu Asn Lys Cys Gly Leu Phe  
 740 745 750  
 Met Cys Ile Ala Val Asn Leu Cys Gly Lys Ala Gly Pro Gly Ala Lys  
 755 760 765  
 Gly Lys Asp Met Glu Glu Gly Lys Ala Ala Phe Ser Lys Asp Glu Ser  
 770 775 780  
 Lys Glu Pro Ile Val Glu Val Arg Thr Glu Glu Glu Arg Thr Pro Asn  
 785 790 795 800  
 His Asp Gly Gly Lys His Thr Glu Pro Asn Glu Thr Thr Pro Leu Thr  
 805 810 815  
 Glu Pro Glu Lys Gly Pro Val Glu Ala Lys Pro Glu Cys Gln Glu Thr



-continued

---

His Asp Phe	His Val Ile	Val Glu Glu	Pro Pro Arg	Trp Thr Lys	Lys	
	325		330		335	
Pro Gln Ser	Ala Val Tyr	Ser Thr Gly	Ser Asn Gly	Ile Leu Leu	Cys	
	340		345	350		
Glu Ala Glu	Gly Glu Pro	Gln Pro Thr	Ile Lys Trp	Arg Val Asn	Gly	
	355		360	365		
Ser Pro Val	Asp Asn His	Pro Phe Ala	Gly Asp Val	Val Phe Pro	Arg	
	370		375	380		
Glu Ile Ser	Phe Thr Asn	Leu Gln Pro	Asn His Thr	Ala Val Tyr	Gln	
	385		390	395	400	
Cys Glu Ala	Ser Asn Val	His Gly Thr	Ile Leu Ala	Asn Ala Asn	Ile	
	405		410		415	
Asp Val Val	Asp Val Arg	Pro Leu Ile	Gln Thr Lys	Asp Gly Glu	Asn	
	420		425	430		
Tyr Ala Thr	Val Val Gly	Tyr Ser Ala	Phe Leu His	Cys Glu Phe	Phe	
	435		440	445		
Ala Ser Pro	Glu Ala Val	Val Ser Trp	Gln Lys Val	Glu Glu Val	Lys	
	450		455	460		
Pro Leu Glu	Gly Arg Arg	Tyr His Ile	Tyr Glu Asn	Gly Thr Leu	Gln	
	465		470	475	480	
Ile Asn Arg	Thr Thr Glu	Glu Asp Ala	Gly Ser Tyr	Ser Cys Trp	Val	
	485		490		495	
Glu Asn Ala	Ile Gly Lys	Thr Ala Val	Thr Ala Asn	Leu Asp Ile	Arg	
	500		505	510		
Asn Ala Thr	Lys Leu Arg	Val Ser Pro	Lys Asn Pro	Arg Ile Pro	Lys	
	515		520	525		
Leu His Met	Leu Glu Leu	His Cys Glu	Ser Lys Cys	Asp Ser His	Leu	
	530		535	540		
Lys His Ser	Leu Lys Leu	Ser Trp Ser	Lys Asp Gly	Glu Ala Phe	Glu	
	545		550	555	560	
Ile Asn Gly	Thr Glu Asp	Gly Arg Ile	Ile Ile Asp	Gly Ala Asn	Leu	
	565		570		575	
Thr Ile Ser	Asn Val Thr	Leu Glu Asp	Gln Gly Ile	Tyr Cys Cys	Ser	
	580		585	590		
Ala His Thr	Ala Leu Asp	Ser Ala Ala	Asp Ile Thr	Gln Val Thr	Val	
	595		600	605		
Leu Asp Val	Pro Asp Pro	Pro Glu Asn	Leu His Leu	Ser Glu Arg	Gln	
	610		615	620		
Asn Arg Ser	Val Arg Leu	Thr Trp Glu	Ala Gly Ala	Asp His Asn	Ser	
	625		630	635	640	
Asn Ile Ser	Glu Tyr Ile	Val Glu Phe	Glu Gly Asn	Lys Glu Glu	Pro	
	645		650		655	
Gly Arg Trp	Glu Glu Leu	Thr Arg Val	Gln Gly Lys	Lys Thr Thr	Val	
	660		665	670		
Ile Leu Pro	Leu Ala Pro	Phe Val Arg	Tyr Gln Phe	Arg Val Ile	Ala	
	675		680	685		
Val Asn Glu	Val Gly Arg	Ser Gln Pro	Ser Gln Pro	Ser Asp His	His	
	690		695	700		
Glu Thr Pro	Pro Ala Ala	Pro Asp Arg	Asn Pro Gln	Asn Ile Arg	Val	
	705		710	715	720	
Gln Ala Ser	Gln Pro Lys	Glu Met Ile	Ile Ile Lys	Trp Glu Pro	Leu Lys	





-continued

---

Lys Asp Glu Thr Phe Gly Glu Tyr Ser Asp Ser Asp Glu Lys Pro  
 1130 1135 1140

Leu Lys Gly Ser Leu Arg Ser Leu Asn Arg Asp Met Gln Pro Thr  
 1145 1150 1155

Glu Ser Ala Asp Ser Leu Val Glu Tyr Gly Glu Gly Asp His Gly  
 1160 1165 1170

Leu Phe Ser Glu Asp Gly Ser Phe Ile Gly Ala Tyr Ala Gly Ser  
 1175 1180 1185

Lys Glu Lys Gly Ser Val Glu Ser Asn Gly Ser Ser Thr Ala Thr  
 1190 1195 1200

Phe Pro Leu Arg Ala  
 1205

<210> SEQ ID NO 4  
 <211> LENGTH: 1347  
 <212> TYPE: PRT  
 <213> ORGANISM: homo sapiens

<400> SEQUENCE: 4

Met Ala Arg Gln Pro Pro Pro Pro Trp Val His Ala Ala Phe Leu Leu  
 1 5 10 15

Cys Leu Leu Ser Leu Gly Gly Ala Ile Glu Ile Pro Met Asp Pro Ser  
 20 25 30

Ile Gln Asn Glu Leu Thr Gln Pro Pro Thr Ile Thr Lys Gln Ser Ala  
 35 40 45

Lys Asp His Ile Val Asp Pro Arg Asp Asn Ile Leu Ile Glu Cys Glu  
 50 55 60

Ala Lys Gly Asn Pro Ala Pro Ser Phe His Trp Thr Arg Asn Ser Arg  
 65 70 75 80

Phe Phe Asn Ile Ala Lys Asp Pro Arg Val Ser Met Arg Arg Arg Ser  
 85 90 95

Gly Thr Leu Val Ile Asp Phe Arg Ser Gly Gly Arg Pro Glu Glu Tyr  
 100 105 110

Glu Gly Glu Tyr Gln Cys Phe Ala Arg Asn Lys Phe Gly Thr Ala Leu  
 115 120 125

Ser Asn Arg Ile Arg Leu Gln Val Ser Lys Ser Pro Leu Trp Pro Lys  
 130 135 140

Glu Asn Leu Asp Pro Val Val Val Gln Glu Gly Ala Pro Leu Thr Leu  
 145 150 155 160

Gln Cys Asn Pro Pro Pro Gly Leu Pro Ser Pro Val Ile Phe Trp Met  
 165 170 175

Ser Ser Ser Met Glu Pro Ile Thr Gln Asp Lys Arg Val Ser Gln Gly  
 180 185 190

His Asn Gly Asp Leu Tyr Phe Ser Asn Val Met Leu Gln Asp Met Gln  
 195 200 205

Thr Asp Tyr Ser Cys Asn Ala Arg Phe His Phe Thr His Thr Ile Gln  
 210 215 220

Gln Lys Asn Pro Phe Thr Leu Lys Val Leu Thr Thr Arg Gly Val Ala  
 225 230 235 240

Glu Arg Thr Pro Ser Phe Met Tyr Pro Gln Gly Thr Ala Ser Ser Gln  
 245 250 255

Met Val Leu Arg Gly Met Asp Leu Leu Leu Glu Cys Ile Ala Ser Gly

-continued

260			265			270									
Val	Pro	Thr	Pro	Asp	Ile	Ala	Trp	Tyr	Lys	Lys	Gly	Gly	Asp	Leu	Pro
	275						280						285		
Ser	Asp	Lys	Ala	Lys	Phe	Glu	Asn	Phe	Asn	Lys	Ala	Leu	Arg	Ile	Thr
	290						295						300		
Asn	Val	Ser	Glu	Glu	Asp	Ser	Gly	Glu	Tyr	Phe	Cys	Leu	Ala	Ser	Asn
	305				310						315				320
Lys	Met	Gly	Ser	Ile	Arg	His	Thr	Ile	Ser	Val	Arg	Val	Lys	Ala	Ala
				325						330					335
Pro	Tyr	Trp	Leu	Asp	Glu	Pro	Lys	Asn	Leu	Ile	Leu	Ala	Pro	Gly	Glu
				340						345					350
Asp	Gly	Arg	Leu	Val	Cys	Arg	Ala	Asn	Gly	Asn	Pro	Lys	Pro	Thr	Val
		355					360						365		
Gln	Trp	Met	Val	Asn	Gly	Glu	Pro	Leu	Gln	Ser	Ala	Pro	Pro	Asn	Pro
	370						375								380
Asn	Arg	Glu	Val	Ala	Gly	Asp	Thr	Ile	Ile	Phe	Arg	Asp	Thr	Gln	Ile
	385				390						395				400
Ser	Ser	Arg	Ala	Val	Tyr	Gln	Cys	Asn	Thr	Ser	Asn	Glu	His	Gly	Tyr
				405						410					415
Leu	Leu	Ala	Asn	Ala	Phe	Val	Ser	Val	Leu	Asp	Val	Pro	Pro	Arg	Met
				420						425					430
Leu	Ser	Pro	Arg	Asn	Gln	Leu	Ile	Arg	Val	Ile	Leu	Tyr	Asn	Arg	Thr
		435					440						445		
Arg	Leu	Asp	Cys	Pro	Phe	Phe	Gly	Ser	Pro	Ile	Pro	Thr	Leu	Arg	Trp
	450						455						460		
Phe	Lys	Asn	Gly	Gln	Gly	Ser	Asn	Leu	Asp	Gly	Gly	Asn	Tyr	His	Val
	465				470					475					480
Tyr	Glu	Asn	Gly	Ser	Leu	Glu	Ile	Lys	Met	Ile	Arg	Lys	Glu	Asp	Gln
				485						490					495
Gly	Ile	Tyr	Thr	Cys	Val	Ala	Thr	Asn	Ile	Leu	Gly	Lys	Ala	Glu	Asn
				500						505					510
Gln	Val	Arg	Leu	Glu	Val	Lys	Asp	Pro	Thr	Arg	Ile	Tyr	Arg	Met	Pro
		515					520						525		
Glu	Asp	Gln	Val	Ala	Arg	Arg	Gly	Thr	Thr	Val	Gln	Leu	Glu	Cys	Arg
	530						535						540		
Val	Lys	His	Asp	Pro	Ser	Leu	Lys	Leu	Thr	Val	Ser	Trp	Leu	Lys	Asp
	545				550						555				560
Asp	Glu	Pro	Leu	Tyr	Ile	Gly	Asn	Arg	Met	Lys	Lys	Glu	Asp	Asp	Ser
				565						570					575
Leu	Thr	Ile	Phe	Gly	Val	Ala	Glu	Arg	Asp	Gln	Gly	Ser	Tyr	Thr	Cys
				580						585					590
Val	Ala	Ser	Thr	Glu	Leu	Asp	Gln	Asp	Leu	Ala	Lys	Ala	Tyr	Leu	Thr
				595			600						605		
Val	Leu	Ala	Asp	Gln	Ala	Thr	Pro	Thr	Asn	Arg	Leu	Ala	Ala	Leu	Pro
	610						615						620		
Lys	Gly	Arg	Pro	Asp	Arg	Pro	Arg	Asp	Leu	Glu	Leu	Thr	Asp	Leu	Ala
	625				630					635					640
Glu	Arg	Ser	Val	Arg	Leu	Thr	Trp	Ile	Pro	Gly	Asp	Ala	Asn	Asn	Ser
				645						650					655
Pro	Ile	Thr	Asp	Tyr	Val	Val	Gln	Phe	Glu	Glu	Asp	Gln	Phe	Gln	Pro
				660						665					670

-continued

---

Gly Val Trp His Asp His Ser Lys Tyr Pro Gly Ser Val Asn Ser Ala  
 675 680 685  
 Val Leu Arg Leu Ser Pro Tyr Val Asn Tyr Gln Phe Arg Val Ile Ala  
 690 695 700  
 Ile Asn Glu Val Gly Ser Ser His Pro Ser Leu Pro Ser Glu Arg Tyr  
 705 710 715 720  
 Arg Thr Ser Gly Ala Pro Pro Glu Ser Asn Pro Gly Asp Val Lys Gly  
 725 730 735  
 Glu Gly Thr Arg Lys Asn Asn Met Glu Ile Thr Trp Thr Pro Met Asn  
 740 745 750  
 Ala Thr Ser Ala Phe Gly Pro Asn Leu Arg Tyr Ile Val Lys Trp Arg  
 755 760 765  
 Arg Arg Glu Thr Arg Glu Ala Trp Asn Asn Val Thr Val Trp Gly Ser  
 770 775 780  
 Arg Tyr Val Val Gly Gln Thr Pro Val Tyr Val Pro Tyr Glu Ile Arg  
 785 790 795 800  
 Val Gln Ala Glu Asn Asp Phe Gly Lys Gly Pro Glu Pro Glu Ser Val  
 805 810 815  
 Ile Gly Tyr Ser Gly Glu Asp Tyr Pro Arg Ala Ala Pro Thr Glu Val  
 820 825 830  
 Lys Val Arg Val Met Asn Ser Thr Ala Ile Ser Leu Gln Trp Asn Arg  
 835 840 845  
 Val Tyr Ser Asp Thr Val Gln Gly Gln Leu Arg Glu Tyr Arg Ala Tyr  
 850 855 860  
 Tyr Trp Arg Glu Ser Ser Leu Leu Lys Asn Leu Trp Val Ser Gln Lys  
 865 870 875 880  
 Arg Gln Gln Ala Ser Phe Pro Gly Asp Arg Leu Arg Gly Val Val Ser  
 885 890 895  
 Arg Leu Phe Pro Tyr Ser Asn Tyr Lys Leu Glu Met Val Val Val Asn  
 900 905 910  
 Gly Arg Gly Asp Gly Pro Arg Ser Glu Thr Lys Glu Phe Thr Thr Pro  
 915 920 925  
 Glu Gly Val Pro Ser Ala Pro Arg Arg Phe Arg Val Arg Gln Pro Asn  
 930 935 940  
 Leu Glu Thr Ile Asn Leu Glu Trp Asp His Pro Glu His Pro Asn Gly  
 945 950 955 960  
 Ile Met Ile Gly Tyr Thr Leu Lys Tyr Val Ala Phe Asn Gly Thr Lys  
 965 970 975  
 Val Gly Lys Gln Ile Val Glu Asn Phe Ser Pro Asn Gln Thr Lys Phe  
 980 985 990  
 Thr Val Gln Arg Thr Asp Pro Val Ser Arg Tyr Arg Phe Thr Leu Ser  
 995 1000 1005  
 Ala Arg Thr Gln Val Gly Ser Gly Glu Ala Val Thr Glu Glu Ser  
 1010 1015 1020  
 Pro Ala Pro Pro Asn Glu Ala Thr Pro Thr Ala Ala Pro Pro Thr  
 1025 1030 1035  
 Leu Pro Pro Thr Thr Val Gly Ala Thr Gly Ala Val Ser Ser Thr  
 1040 1045 1050  
 Asp Ala Thr Ala Ile Ala Ala Thr Thr Glu Ala Thr Thr Val Pro  
 1055 1060 1065

-continued

---

Ile	Ile	Pro	Thr	Val	Ala	Pro	Thr	Thr	Ile	Ala	Thr	Thr	Thr	Thr
	1070					1075					1080			
Val	Ala	Thr	Thr	Thr	Thr	Thr	Thr	Ala	Ala	Ala	Thr	Thr	Thr	Thr
	1085					1090					1095			
Glu	Ser	Pro	Pro	Thr	Thr	Thr	Ser	Gly	Thr	Lys	Ile	His	Glu	Ser
	1100					1105					1110			
Ala	Pro	Asp	Glu	Gln	Ser	Ile	Trp	Asn	Val	Thr	Val	Leu	Pro	Asn
	1115					1120					1125			
Ser	Lys	Trp	Ala	Asn	Ile	Thr	Trp	Lys	His	Asn	Phe	Gly	Pro	Gly
	1130					1135					1140			
Thr	Asp	Phe	Val	Val	Glu	Tyr	Ile	Asp	Ser	Asn	His	Thr	Lys	Lys
	1145					1150					1155			
Thr	Val	Pro	Val	Lys	Ala	Gln	Ala	Gln	Pro	Ile	Gln	Leu	Thr	Asp
	1160					1165					1170			
Leu	Tyr	Pro	Gly	Met	Thr	Tyr	Thr	Leu	Arg	Val	Tyr	Ser	Arg	Asp
	1175					1180					1185			
Asn	Glu	Gly	Ile	Ser	Ser	Thr	Val	Ile	Thr	Phe	Met	Thr	Ser	Thr
	1190					1195					1200			
Ala	Tyr	Thr	Asn	Asn	Gln	Ala	Asp	Ile	Ala	Thr	Gln	Gly	Trp	Phe
	1205					1210					1215			
Ile	Gly	Leu	Met	Cys	Ala	Ile	Ala	Leu	Leu	Val	Leu	Ile	Leu	Leu
	1220					1225					1230			
Ile	Val	Cys	Phe	Ile	Lys	Arg	Ser	Arg	Gly	Gly	Lys	Tyr	Pro	Val
	1235					1240					1245			
Arg	Glu	Lys	Lys	Asp	Val	Pro	Leu	Gly	Pro	Glu	Asp	Pro	Lys	Glu
	1250					1255					1260			
Glu	Asp	Gly	Ser	Phe	Asp	Tyr	Ser	Asp	Glu	Asp	Asn	Lys	Pro	Leu
	1265					1270					1275			
Gln	Gly	Ser	Gln	Thr	Ser	Leu	Asp	Gly	Thr	Ile	Lys	Gln	Gln	Glu
	1280					1285					1290			
Ser	Asp	Asp	Ser	Leu	Val	Asp	Tyr	Gly	Glu	Gly	Gly	Glu	Gly	Gln
	1295					1300					1305			
Phe	Asn	Glu	Asp	Gly	Ser	Phe	Ile	Gly	Gln	Tyr	Thr	Val	Lys	Lys
	1310					1315					1320			
Asp	Lys	Glu	Glu	Thr	Glu	Gly	Asn	Glu	Ser	Ser	Glu	Ala	Thr	Ser
	1325					1330					1335			
Pro	Val	Asn	Ala	Ile	Tyr	Ser	Leu	Ala						
	1340					1345								

---

We claim:

1. A method of recording and/or stimulating a neural signal in a subject, comprising:

(a) implanting a neural probe for recording and/or stimulating the neural signal into neuronal tissue in the subject, wherein the probe comprises:

one or more electrodes comprising a surface exposed to the exterior of the probe;

insulated electrical conductors having non-insulated ends, wherein the electrical conductors extend through the probe and one or more of the non-insulated ends contact the electrodes;

a parylene C insulating layer coating a portion of the exterior surface of the probe, except for the surface of the electrodes exposed to the exterior of the probe;

an effective amount of L1 polypeptide or a functional fragment thereof on the exterior surface of the probe;

(b) connecting the probe to a recording and/or stimulating apparatus via one or more electrical leads; and

(c) recording and/or stimulating the neural signal from the neuronal tissue.

2. The method of claim 1, wherein the effective amount of the L1 polypeptide or functional fragment thereof comprises an amount sufficient to allow recording of at least four sortable neural units from at least one electrode after the probe has been implanted for at least six months.

3. The method of claim 1, comprising recording and/or stimulating the neural signal after the probe has been implanted in the neuronal tissue for at least one year.

4. The method of claim 1, wherein recording the neural signal comprises recording at least four sortable neural units from the at least one electrode after the probe has been implanted in the neuronal tissue for at least one year.

5. The method of claim 1, wherein the functional fragment of the L1 polypeptide comprises or consists of:

- an L1 extracellular domain;
- an Ig1, Ig2, Ig3, or Ig4 domain of L1, or a combination of two or more thereof;
- an amino acid sequence at least 90% identical to amino acids 20-1120 of SEQ ID NO: 1; or
- the amino acid sequence set forth as amino acids 20-1120 of SEQ ID NO: 1; or the L1 polypeptide comprises or consists of:
  - an amino acid sequence at least 90% identical SEQ ID NO: 1; or
  - the amino acid sequence set forth as SEQ ID NO: 1.

6. The method of claim 1, wherein the L1 polypeptide or functional fragment is a monkey, rat, mouse or human L1 polypeptide or functional fragment thereof.

7. The method of claim 1, wherein the subject is a human.

8. The method of claim 1, wherein the L1 polypeptide or functional fragment thereof is conjugated to the insulating layer.

9. The method of claim 1, wherein the probe comprises from about 0.1 ng/mm<sup>2</sup> to about 2.0 ng/mm<sup>2</sup> L1 polypeptide or functional fragment thereof on the exterior surface.

10. A neural probe for recording and/or stimulating a neural signal in a subject, comprising:

- one or more electrodes comprising a surface exposed to the exterior of the probe;
- insulated electrical conductors having non-insulated ends, wherein the electrical conductors extend through the probe and one or more of the non-insulated ends contact the electrodes;
- a parylene C insulating layer coating a portion of the exterior surface of the probe, except for the surface of the electrodes exposed to the exterior of the probe; and

an effective amount of L1 polypeptide or a functional fragment thereof on the exterior surface of the probe.

11. The neural probe of claim 10, wherein the effective amount of the L1 polypeptide or functional fragment thereof comprises an amount sufficient to allow recording of at least four sortable neural units from at least one electrode after the probe has been implanted for at least six months.

12. The neural probe of claim 10, wherein the functional fragment of the L1 polypeptide comprises or consists of:

- an L1 extracellular domain;
- an Ig1, Ig2, Ig3, or Ig4 domain of L1, or a combination of two or more thereof;
- an amino acid sequence at least 90% identical to amino acids 20-1120 of SEQ ID NO: 1; or
- the amino acid sequence set forth as amino acids 20-1120 of SEQ ID NO: 1; or the L1 polypeptide comprises or consists of:
  - an amino acid sequence at least 90% identical SEQ ID NO: 1; or
  - the amino acid sequence set forth as SEQ ID NO: 1.

13. The neural probe of claim 10, wherein the L1 polypeptide is a monkey, rat, mouse or human L1 polypeptide.

14. The neural probe of claim 10, wherein the probe comprises from about 0.1 ng/mm<sup>2</sup> to about 2.0 ng/mm<sup>2</sup> L1 polypeptide or functional fragment thereof on the exterior surface.

15. A device for recording and/or stimulating a neural signal in a subject, comprising the probe of claim 10.

16. The device of claim 17, wherein the device is a microarray or a deep brain stimulator.

17. The device of claim 17, connected to a recording and/or stimulation apparatus.

18. A method of making the probe of claim 10, comprising: conjugating an effective amount of an L1 polypeptide or a functional fragment thereof to an exterior surface of a neural probe for recording and/or stimulating a neural signal in a subject.

\* \* \* \* \*